cart158 personal page - To The Moon

cart158

No personal profile

119Follow

1Followers

0Topic

0Badge

2021-09-14

I like abnb

Sorry, the original content has been removed

2021-09-13

Should buy this stock now?

Sorry, the original content has been removed

2021-09-13

Good good

3 Stocks That Could Soar 50% or Better, According to Wall Street

2021-09-10

Time to buy?

Sorry, the original content has been removed

2021-09-10

How how xia

Malaysia's Top Glove says cleared to resume business with U.S.

2021-09-10

Not worth

Sorry, the original content has been removed

2021-09-07

But share today start drop wo

Sorry, the original content has been removed

2021-08-23

want sell now?

@Goh Tang Peng:$Lion-OCBC Sec HSTECH S$(HST.SI)$ die la die la, regretted buying, HK market look so weak again and again, may go down further to $0.850 hsien ah hsien ah.

2021-08-13

I wonder the whole world have enough vivid vaccine or not

Americans With Weak Immune Systems Will Get 3 Covid Shots

2021-08-13

Time to buy now? How?

Sorry, the original content has been removed

2021-08-13

I want to invest also

Sorry, the original content has been removed

2021-08-13

Good good

Americans With Weak Immune Systems Will Get 3 Covid Shots

2021-08-09

Think stock will go up?

Sorry, the original content has been removed

2021-08-03

Hope time to buy the stock come

Apple Will Have To Face Patent Infringement Lawsuit Over Apple Watch Heart Rate Sensor, Rules Court

2021-08-01

Hope it's become better

It’s Open Season on Closed-End Fund Activists. How Fund Holders Can Win—and Lose

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3556954148323654","uuid":"3556954148323654","gmtCreate":1593962174927,"gmtModify":1593962174927,"name":"cart158","pinyin":"cart158","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":119,"tweetSize":16,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.08.14","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":886164377,"gmtCreate":1631576203999,"gmtModify":1676530577527,"author":{"id":"3556954148323654","authorId":"3556954148323654","name":"cart158","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3556954148323654","authorIdStr":"3556954148323654"},"themes":[],"htmlText":"I like abnb","listText":"I like abnb","text":"I like abnb","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/886164377","repostId":"1144988530","repostType":4,"isVote":1,"tweetType":1,"viewCount":418,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":886053880,"gmtCreate":1631540527340,"gmtModify":1676530570105,"author":{"id":"3556954148323654","authorId":"3556954148323654","name":"cart158","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3556954148323654","authorIdStr":"3556954148323654"},"themes":[],"htmlText":"Should buy this stock now?","listText":"Should buy this stock now?","text":"Should buy this stock now?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/886053880","repostId":"2167586988","repostType":4,"isVote":1,"tweetType":1,"viewCount":371,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":886059810,"gmtCreate":1631540494730,"gmtModify":1676530570081,"author":{"id":"3556954148323654","authorId":"3556954148323654","name":"cart158","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3556954148323654","authorIdStr":"3556954148323654"},"themes":[],"htmlText":"Good good","listText":"Good good","text":"Good good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/886059810","repostId":"2167583295","repostType":4,"repost":{"id":"2167583295","pubTimestamp":1631538519,"share":"https://ttm.financial/m/news/2167583295?lang=&edition=fundamental","pubTime":"2021-09-13 21:08","market":"us","language":"en","title":"3 Stocks That Could Soar 50% or Better, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2167583295","media":"Motley Fool","summary":"All three of these growth stocks are poised to put up big gains once more investors land on the same page as investment bank analysts who follow them.","content":"<p>If you saw someone on a street corner selling dollars for $0.66, you'd probably drop everything to take advantage of such a great deal. That's what's happening with three growth stocks right now, according to Wall Street analysts who follow them.</p>\n<p>All of these companies have consensus price targets on them that suggest they're worth at least 50% more than their recent prices. Read on to see why expectations from investment bankers aren't lining up with those of everyday investors right now.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f2ce48b7a968efa5502d805a17dd3d90\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Coinbase Global</h2>\n<p><b>Coinbase Global</b> (NASDAQ:COIN) shares are down about 27% since the cryptocurrency trading platform made its stock market debut in April. Investment bank analysts who get paid to follow Coinbase think it's just a matter of time before the stock rebounds and then some. The consensus target on Coinbase at the moment represents a 51% premium over the price it's been trading at.</p>\n<p>Coinbase shares took a tumble recently, after the company disclosed an SEC investigation of its plan to lend consumers stable coins in exchange for interest payments. The SEC intends to sue Coinbase if it tries to launch Lend because the program resembles an unregistered security.</p>\n<p>Right now, it seems the only way to get the SEC to quit trying to regulate cryptocurrency-backed investments is to make them resemble the traditional instruments they intend to replace. Investors will want to keep an eye open for more government interventions that prevent cryptocurrencies from gaining traction.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e4c2d9360d24d6b0b3aad62fffd45cf0\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Inari Medical</h2>\n<p><b>Inari Medical</b> (NASDAQ:NARI) shares are down about 37% since reaching their peak this March. Wall Street analysts are expecting a swift rebound and then some. The average target on this medical-device stock is 50% above its price at the moment.</p>\n<p>Sales of Inari's blood clot-removal devices haven't risen as fast as Wall Street had expected at the beginning of 2021. In January, the company's Flowtriever system received FDA approval to treat pulmonary embolisms.</p>\n<p>This healthcare stock's valuation may have gotten a little bit ahead of itself, but Wall Street is probably right to expect strong growth ahead. Pulmonary embolisms are the leading cause of preventable deaths in hospitals and the third largest cause of cardiovascular death overall.</p>\n<p>The Flowtriever is the first minimally invasive device approved by the FDA to clear out life-threatening blood clots that make it hard for the heart to receive blood from the lungs. In lieu of a risky surgical procedure, pulmonary embolisms are traditionally treated with powerful blood-thinning agents. Compared with either option, clot removal with Flowtriever gets patients out of the hospital a lot faster and with far less risk.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/538c219d544d79885c08b1325abb11ed\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Amyris</h2>\n<p><b>Amyris</b> (NASDAQ:AMRS) shares are down around 40% since the synthetic biology (synbio) stock peaked in April. The average investment bank analyst following the company thinks the recent weakness is a strong bargain opportunity. The consensus price target of $22 per share represents a 62% premium over recent prices.</p>\n<p>The recent implosion of <b>Zymergen</b>, a much younger synbio company, hasn't done Amyris' stock price any favors. While both companies manufacture high-value ingredients with the assistance of microorganisms, Amyris is the only synbio operation that isn't losing heaps of money right now.</p>\n<p>Amyris' lead product, squalane, is traditionally harvested from shark livers at great expense and used to produce high-end moisturizers. Amyris sells some of the squalane it produces to skincare businesses, and it makes its own brand, called Biossance.</p>\n<p>High-margin revenue from Biossance is rising quickly enough to justify Amyris' recent $4 billion market cap on its own. There's a lot more coming through the company's hyperefficient new product pipeline, too.</p>\n<p>In addition to squalane, Amyris has 12 more ingredients already on the market and 24 new ones expected to launch by the end of 2025. If just <a href=\"https://laohu8.com/S/AONE.U\">one</a> helps a new brand become as successful as Biossance, this life science stock could blow right past today's price targets.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Could Soar 50% or Better, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Could Soar 50% or Better, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-13 21:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/13/3-stocks-that-could-soar-45-or-better-according-to/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you saw someone on a street corner selling dollars for $0.66, you'd probably drop everything to take advantage of such a great deal. That's what's happening with three growth stocks right now, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/13/3-stocks-that-could-soar-45-or-better-according-to/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COIN":"Coinbase Global, Inc.","AMRS":"阿米瑞斯","NARI":"Inari Medical, Inc."},"source_url":"https://www.fool.com/investing/2021/09/13/3-stocks-that-could-soar-45-or-better-according-to/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167583295","content_text":"If you saw someone on a street corner selling dollars for $0.66, you'd probably drop everything to take advantage of such a great deal. That's what's happening with three growth stocks right now, according to Wall Street analysts who follow them.\nAll of these companies have consensus price targets on them that suggest they're worth at least 50% more than their recent prices. Read on to see why expectations from investment bankers aren't lining up with those of everyday investors right now.\nImage source: Getty Images.\nCoinbase Global\nCoinbase Global (NASDAQ:COIN) shares are down about 27% since the cryptocurrency trading platform made its stock market debut in April. Investment bank analysts who get paid to follow Coinbase think it's just a matter of time before the stock rebounds and then some. The consensus target on Coinbase at the moment represents a 51% premium over the price it's been trading at.\nCoinbase shares took a tumble recently, after the company disclosed an SEC investigation of its plan to lend consumers stable coins in exchange for interest payments. The SEC intends to sue Coinbase if it tries to launch Lend because the program resembles an unregistered security.\nRight now, it seems the only way to get the SEC to quit trying to regulate cryptocurrency-backed investments is to make them resemble the traditional instruments they intend to replace. Investors will want to keep an eye open for more government interventions that prevent cryptocurrencies from gaining traction.\nImage source: Getty Images.\nInari Medical\nInari Medical (NASDAQ:NARI) shares are down about 37% since reaching their peak this March. Wall Street analysts are expecting a swift rebound and then some. The average target on this medical-device stock is 50% above its price at the moment.\nSales of Inari's blood clot-removal devices haven't risen as fast as Wall Street had expected at the beginning of 2021. In January, the company's Flowtriever system received FDA approval to treat pulmonary embolisms.\nThis healthcare stock's valuation may have gotten a little bit ahead of itself, but Wall Street is probably right to expect strong growth ahead. Pulmonary embolisms are the leading cause of preventable deaths in hospitals and the third largest cause of cardiovascular death overall.\nThe Flowtriever is the first minimally invasive device approved by the FDA to clear out life-threatening blood clots that make it hard for the heart to receive blood from the lungs. In lieu of a risky surgical procedure, pulmonary embolisms are traditionally treated with powerful blood-thinning agents. Compared with either option, clot removal with Flowtriever gets patients out of the hospital a lot faster and with far less risk.\nImage source: Getty Images.\nAmyris\nAmyris (NASDAQ:AMRS) shares are down around 40% since the synthetic biology (synbio) stock peaked in April. The average investment bank analyst following the company thinks the recent weakness is a strong bargain opportunity. The consensus price target of $22 per share represents a 62% premium over recent prices.\nThe recent implosion of Zymergen, a much younger synbio company, hasn't done Amyris' stock price any favors. While both companies manufacture high-value ingredients with the assistance of microorganisms, Amyris is the only synbio operation that isn't losing heaps of money right now.\nAmyris' lead product, squalane, is traditionally harvested from shark livers at great expense and used to produce high-end moisturizers. Amyris sells some of the squalane it produces to skincare businesses, and it makes its own brand, called Biossance.\nHigh-margin revenue from Biossance is rising quickly enough to justify Amyris' recent $4 billion market cap on its own. There's a lot more coming through the company's hyperefficient new product pipeline, too.\nIn addition to squalane, Amyris has 12 more ingredients already on the market and 24 new ones expected to launch by the end of 2025. If just one helps a new brand become as successful as Biossance, this life science stock could blow right past today's price targets.","news_type":1},"isVote":1,"tweetType":1,"viewCount":266,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":883269260,"gmtCreate":1631244840250,"gmtModify":1676530507565,"author":{"id":"3556954148323654","authorId":"3556954148323654","name":"cart158","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3556954148323654","authorIdStr":"3556954148323654"},"themes":[],"htmlText":"Time to buy?","listText":"Time to buy?","text":"Time to buy?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883269260","repostId":"2166495033","repostType":4,"isVote":1,"tweetType":1,"viewCount":331,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":883269644,"gmtCreate":1631244823288,"gmtModify":1676530507549,"author":{"id":"3556954148323654","authorId":"3556954148323654","name":"cart158","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3556954148323654","authorIdStr":"3556954148323654"},"themes":[],"htmlText":"How how xia","listText":"How how xia","text":"How how xia","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883269644","repostId":"2166674328","repostType":4,"repost":{"id":"2166674328","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1631240944,"share":"https://ttm.financial/m/news/2166674328?lang=&edition=fundamental","pubTime":"2021-09-10 10:29","market":"sg","language":"en","title":"Malaysia's Top Glove says cleared to resume business with U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2166674328","media":"Reuters","summary":"KUALA LUMPUR, Sept 10 (Reuters) - Malaysia's Top Glove Corporation said on Friday it has been allowe","content":"<p>KUALA LUMPUR, Sept 10 (Reuters) - Malaysia's Top Glove Corporation said on Friday it has been allowed to resume exporting and selling gloves to the United States, following an import ban imposed since last year.</p>\n<p>U.S. authorities had banned disposable gloves made by the world's largest medical glove maker since July 2020, saying in March it had sufficient information to determine labour abuses at the company.</p>\n<p>Top Glove said in a securities filing its disposable gloves would be admissible at all U.S. ports of entry as of Sept. 10.</p>\n<p>The firm said in April it had resolved all indicators of forced labour in its operations, citing a report by independent consultant Impactt Limited.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Malaysia's Top Glove says cleared to resume business with U.S.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMalaysia's Top Glove says cleared to resume business with U.S.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-09-10 10:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>KUALA LUMPUR, Sept 10 (Reuters) - Malaysia's Top Glove Corporation said on Friday it has been allowed to resume exporting and selling gloves to the United States, following an import ban imposed since last year.</p>\n<p>U.S. authorities had banned disposable gloves made by the world's largest medical glove maker since July 2020, saying in March it had sufficient information to determine labour abuses at the company.</p>\n<p>Top Glove said in a securities filing its disposable gloves would be admissible at all U.S. ports of entry as of Sept. 10.</p>\n<p>The firm said in April it had resolved all indicators of forced labour in its operations, citing a report by independent consultant Impactt Limited.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TPGVF":"Top Glove Corp.","TGLVY":"Top Glove Corp.","BVA.SI":"顶级手套有限公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166674328","content_text":"KUALA LUMPUR, Sept 10 (Reuters) - Malaysia's Top Glove Corporation said on Friday it has been allowed to resume exporting and selling gloves to the United States, following an import ban imposed since last year.\nU.S. authorities had banned disposable gloves made by the world's largest medical glove maker since July 2020, saying in March it had sufficient information to determine labour abuses at the company.\nTop Glove said in a securities filing its disposable gloves would be admissible at all U.S. ports of entry as of Sept. 10.\nThe firm said in April it had resolved all indicators of forced labour in its operations, citing a report by independent consultant Impactt Limited.","news_type":1},"isVote":1,"tweetType":1,"viewCount":351,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":883269386,"gmtCreate":1631244807245,"gmtModify":1676530507541,"author":{"id":"3556954148323654","authorId":"3556954148323654","name":"cart158","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3556954148323654","authorIdStr":"3556954148323654"},"themes":[],"htmlText":"Not worth","listText":"Not worth","text":"Not worth","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/883269386","repostId":"2166434154","repostType":4,"isVote":1,"tweetType":1,"viewCount":403,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":880832797,"gmtCreate":1631029950319,"gmtModify":1676530448609,"author":{"id":"3556954148323654","authorId":"3556954148323654","name":"cart158","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3556954148323654","authorIdStr":"3556954148323654"},"themes":[],"htmlText":"But share today start drop wo","listText":"But share today start drop wo","text":"But share today start drop wo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/880832797","repostId":"2165849354","repostType":4,"isVote":1,"tweetType":1,"viewCount":620,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":832422376,"gmtCreate":1629675881195,"gmtModify":1676530090245,"author":{"id":"3556954148323654","authorId":"3556954148323654","name":"cart158","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3556954148323654","authorIdStr":"3556954148323654"},"themes":[],"htmlText":"want sell now?","listText":"want sell now?","text":"want sell now?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/832422376","repostId":"838742907","repostType":1,"repost":{"id":838742907,"gmtCreate":1629432482109,"gmtModify":1676530039665,"author":{"id":"3582706821016791","authorId":"3582706821016791","name":"Goh Tang Peng","avatar":"https://community-static.tradeup.com/news/bff59b5e90b9a1db84eedde04d8851b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582706821016791","authorIdStr":"3582706821016791"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/HST.SI\">$Lion-OCBC Sec HSTECH S$(HST.SI)$</a>&nbsp;die la die la, regretted buying, HK market look so weak again and again,&nbsp;may go down further&nbsp;to $0.850 hsien ah hsien ah.&nbsp;","listText":"<a href=\"https://laohu8.com/S/HST.SI\">$Lion-OCBC Sec HSTECH S$(HST.SI)$</a>&nbsp;die la die la, regretted buying, HK market look so weak again and again,&nbsp;may go down further&nbsp;to $0.850 hsien ah hsien ah.&nbsp;","text":"$Lion-OCBC Sec HSTECH S$(HST.SI)$ die la die la, regretted buying, HK market look so weak again and again, may go down further to $0.850 hsien ah hsien ah.","images":[{"img":"https://static.tigerbbs.com/49da47558038f7eff00e37570a3c0012","width":"1080","height":"1920"}],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/838742907","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":453,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":897070590,"gmtCreate":1628865134010,"gmtModify":1676529880184,"author":{"id":"3556954148323654","authorId":"3556954148323654","name":"cart158","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3556954148323654","authorIdStr":"3556954148323654"},"themes":[],"htmlText":"I wonder the whole world have enough vivid vaccine or not","listText":"I wonder the whole world have enough vivid vaccine or not","text":"I wonder the whole world have enough vivid vaccine or not","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/897070590","repostId":"1121308321","repostType":4,"repost":{"id":"1121308321","pubTimestamp":1628859436,"share":"https://ttm.financial/m/news/1121308321?lang=&edition=fundamental","pubTime":"2021-08-13 20:57","market":"us","language":"en","title":"Americans With Weak Immune Systems Will Get 3 Covid Shots","url":"https://stock-news.laohu8.com/highlight/detail?id=1121308321","media":"Bloomberg","summary":"Americans with weakened immune systems will be allowed to get three shots of Covid-19 vaccine after ","content":"<p>Americans with weakened immune systems will be allowed to get three shots of Covid-19 vaccine after U.S. regulators authorized giving an extra dose to the most vulnerable people.</p>\n<p>The U.S. Food and Drug Administration’s action expands the use of vaccines fromModerna Inc.and the partnership ofPfizer Inc.andBioNTech SEfor organ transplant recipients and patients with other conditions like cancer that hobble the body’s natural infection-fighting response. The decision doesn’t apply to other fully vaccinated individuals, the agency said in astatement.</p>\n<p>The U.S. is currently facing a surge of infections spawned by the highly infectious delta variant, with more than 117,000 new cases diagnosed yesterday. The FDA’s move was designed to protect those people most likely to be harmed or die from an infection, even after a standard course of shots.</p>\n<p>“The country has entered yet another wave of the Covid-19 pandemic, and the FDA is especially cognizant that immunocompromised people are particularly at risk for severe disease,” said Acting Commissioner Janet Woodcock. “After a thorough review of the available data, the FDA determined that this small, vulnerable group may benefit from a third dose of the Pfizer-BioNTech or Moderna vaccines.”</p>\n<p>Vaccine Access</p>\n<p>The decision could further exacerbate the vaccine inequality that exists across the world. The U.S. is joining countries including Israel, Germany and France in offering boosters to vulnerable groups, while nations including Russia and the United Arab Emirates are giving them even more broadly. The European Union’s drugs regulatorsaidFriday that it’s coordinating with vaccine makers and reviewing data on third shots.</p>\n<p>Meanwhile, dozens of countries have such limited access to the vaccines that they have immunized fewer than 10% of their populations.</p>\n<p>The FDA’s decision was supported by a study published in the New England Journal of Medicine on Wednesday, showing that a third dose of Moderna’s vaccine significantly raised levels of Covid-fighting antibodies in 55% of transplant patients. Among those who got a placebo rather than the extra shot, just 18% generated the desired antibody levels, thestudyfound.</p>\n<p>“Ifeelvery relieved that they are doing this, because it will save lives,” said Janet Handal, a kidney transplant recipient. “I wish that they had done it sooner.”</p>\n<p>While the U.S.-authorized Covid-19 vaccines are highly effective at preventing severe disease, hospitalization and death in most people, booster shots are especially important for transplant patients and others with weak immune systems, who often don’t get adequate responses to their first vaccine course. Immune compromised people compose about 3% of adults, Rochelle Walensky, director of the Centers for Disease Control and Prevention, said on a press call.</p>\n<p>Many patients had sought out extra doses on their own as findings emerged on their responses to vaccines. Dorry Segev, a professor of surgery and epidemiology at Johns Hopkins University, said his research team has observed more than 200 transplant recipients who have gotten third shots, and he suspects many more immunocompromised patients have done so as well.</p>\n<p>Advisers for the CDC raised concerns at a meeting last month about patients getting additional doses in an unsupervised manner and the inequities that could arise.</p>\n<p>“The people who’ve gotten it now are the people who navigate the health care system well, who are willing to go to great lengths,” Segev said. FDA approval “would then expand access of these boosters in a more equitable way to people who might not be as good as navigating the health care system and might have been too shy or too worried about pursuing something.”</p>\n<p>The FDA’s action allows for a third shot at least 28 days after the initial two-dose regimen in organ transplant recipients and patients with conditions “considered to have an equivalent level of immunocompromise.” Immune compromising conditions include blood cancers, HIV, multiple sclerosis and many others. In some cases, patients’ conditions weaken the immune system; in others, it’s their medications. Among the various conditions, the degree of immune suppression may differ.</p>\n<p>Not all patients may develop an antibody response after the third dose, as research so far has shown. Until there’s more information about how much protection patients have after a third dose and until the delta wave subsides, patients should still continue to mask and social distance, Segev said.</p>\n<p>Only those with weakened immune systems will be offered boosters, White House chief medical adviser Anthony Fauci said on NBC’s ”Today” show. For other vaccinated groups, such as the elderly, data is being collected to determine if or when their protection goes “below a critical level.”</p>\n<p>“Right now at this moment, other than the immune-compromised, we’re not going to be giving boosters to people, but we will be following them very carefully, and if they do need it, we’ll be ready to give it to them,” he said.</p>\n<p>About 60% of eligible Americans, age 12 and older, are fully vaccinated, according to the CDC. And while the pace of immunization is rising after falling sharply from a high point in mid-April, the Biden administration is urging people to get shots as infections surge in the U.S., fueled by the delta variant.</p>\n<p>An advisory committee to the CDC is also set to discuss booster doses of Covid–19 vaccine for immunocompromised patients on Friday.</p>\n<p>Handal and other transplant recipients formed Transplant Recipients and Immunocompromised Patient Advocacy Group during the pandemic that has urged the FDA to streamline approval of additional doses for those with weakened immune systems.</p>\n<p>“People that are immunocompromised are continuing to live with the fear that everyonefeltin the early days of Covid,” Handal said in an interview. They’re carrying on with their lives as the world opens up, but “it’s just an undercurrent of fear, and it’s exhausting to live with.”</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Americans With Weak Immune Systems Will Get 3 Covid Shots</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmericans With Weak Immune Systems Will Get 3 Covid Shots\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-13 20:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-13/u-s-clears-third-covid-shot-for-immunocompromised-patients><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Americans with weakened immune systems will be allowed to get three shots of Covid-19 vaccine after U.S. regulators authorized giving an extra dose to the most vulnerable people.\nThe U.S. Food and ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-13/u-s-clears-third-covid-shot-for-immunocompromised-patients\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-08-13/u-s-clears-third-covid-shot-for-immunocompromised-patients","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1121308321","content_text":"Americans with weakened immune systems will be allowed to get three shots of Covid-19 vaccine after U.S. regulators authorized giving an extra dose to the most vulnerable people.\nThe U.S. Food and Drug Administration’s action expands the use of vaccines fromModerna Inc.and the partnership ofPfizer Inc.andBioNTech SEfor organ transplant recipients and patients with other conditions like cancer that hobble the body’s natural infection-fighting response. The decision doesn’t apply to other fully vaccinated individuals, the agency said in astatement.\nThe U.S. is currently facing a surge of infections spawned by the highly infectious delta variant, with more than 117,000 new cases diagnosed yesterday. The FDA’s move was designed to protect those people most likely to be harmed or die from an infection, even after a standard course of shots.\n“The country has entered yet another wave of the Covid-19 pandemic, and the FDA is especially cognizant that immunocompromised people are particularly at risk for severe disease,” said Acting Commissioner Janet Woodcock. “After a thorough review of the available data, the FDA determined that this small, vulnerable group may benefit from a third dose of the Pfizer-BioNTech or Moderna vaccines.”\nVaccine Access\nThe decision could further exacerbate the vaccine inequality that exists across the world. The U.S. is joining countries including Israel, Germany and France in offering boosters to vulnerable groups, while nations including Russia and the United Arab Emirates are giving them even more broadly. The European Union’s drugs regulatorsaidFriday that it’s coordinating with vaccine makers and reviewing data on third shots.\nMeanwhile, dozens of countries have such limited access to the vaccines that they have immunized fewer than 10% of their populations.\nThe FDA’s decision was supported by a study published in the New England Journal of Medicine on Wednesday, showing that a third dose of Moderna’s vaccine significantly raised levels of Covid-fighting antibodies in 55% of transplant patients. Among those who got a placebo rather than the extra shot, just 18% generated the desired antibody levels, thestudyfound.\n“Ifeelvery relieved that they are doing this, because it will save lives,” said Janet Handal, a kidney transplant recipient. “I wish that they had done it sooner.”\nWhile the U.S.-authorized Covid-19 vaccines are highly effective at preventing severe disease, hospitalization and death in most people, booster shots are especially important for transplant patients and others with weak immune systems, who often don’t get adequate responses to their first vaccine course. Immune compromised people compose about 3% of adults, Rochelle Walensky, director of the Centers for Disease Control and Prevention, said on a press call.\nMany patients had sought out extra doses on their own as findings emerged on their responses to vaccines. Dorry Segev, a professor of surgery and epidemiology at Johns Hopkins University, said his research team has observed more than 200 transplant recipients who have gotten third shots, and he suspects many more immunocompromised patients have done so as well.\nAdvisers for the CDC raised concerns at a meeting last month about patients getting additional doses in an unsupervised manner and the inequities that could arise.\n“The people who’ve gotten it now are the people who navigate the health care system well, who are willing to go to great lengths,” Segev said. FDA approval “would then expand access of these boosters in a more equitable way to people who might not be as good as navigating the health care system and might have been too shy or too worried about pursuing something.”\nThe FDA’s action allows for a third shot at least 28 days after the initial two-dose regimen in organ transplant recipients and patients with conditions “considered to have an equivalent level of immunocompromise.” Immune compromising conditions include blood cancers, HIV, multiple sclerosis and many others. In some cases, patients’ conditions weaken the immune system; in others, it’s their medications. Among the various conditions, the degree of immune suppression may differ.\nNot all patients may develop an antibody response after the third dose, as research so far has shown. Until there’s more information about how much protection patients have after a third dose and until the delta wave subsides, patients should still continue to mask and social distance, Segev said.\nOnly those with weakened immune systems will be offered boosters, White House chief medical adviser Anthony Fauci said on NBC’s ”Today” show. For other vaccinated groups, such as the elderly, data is being collected to determine if or when their protection goes “below a critical level.”\n“Right now at this moment, other than the immune-compromised, we’re not going to be giving boosters to people, but we will be following them very carefully, and if they do need it, we’ll be ready to give it to them,” he said.\nAbout 60% of eligible Americans, age 12 and older, are fully vaccinated, according to the CDC. And while the pace of immunization is rising after falling sharply from a high point in mid-April, the Biden administration is urging people to get shots as infections surge in the U.S., fueled by the delta variant.\nAn advisory committee to the CDC is also set to discuss booster doses of Covid–19 vaccine for immunocompromised patients on Friday.\nHandal and other transplant recipients formed Transplant Recipients and Immunocompromised Patient Advocacy Group during the pandemic that has urged the FDA to streamline approval of additional doses for those with weakened immune systems.\n“People that are immunocompromised are continuing to live with the fear that everyonefeltin the early days of Covid,” Handal said in an interview. They’re carrying on with their lives as the world opens up, but “it’s just an undercurrent of fear, and it’s exhausting to live with.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":216,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":894740335,"gmtCreate":1628859995827,"gmtModify":1676529877286,"author":{"id":"3556954148323654","authorId":"3556954148323654","name":"cart158","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3556954148323654","authorIdStr":"3556954148323654"},"themes":[],"htmlText":"Time to buy now? How?","listText":"Time to buy now? How?","text":"Time to buy now? How?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/894740335","repostId":"2159829435","repostType":4,"isVote":1,"tweetType":1,"viewCount":212,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":894757421,"gmtCreate":1628859967563,"gmtModify":1676529877277,"author":{"id":"3556954148323654","authorId":"3556954148323654","name":"cart158","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3556954148323654","authorIdStr":"3556954148323654"},"themes":[],"htmlText":"I want to invest also","listText":"I want to invest also","text":"I want to invest also","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/894757421","repostId":"1118408635","repostType":4,"isVote":1,"tweetType":1,"viewCount":188,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":894757047,"gmtCreate":1628859939689,"gmtModify":1676529877261,"author":{"id":"3556954148323654","authorId":"3556954148323654","name":"cart158","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3556954148323654","authorIdStr":"3556954148323654"},"themes":[],"htmlText":"Good good","listText":"Good good","text":"Good good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/894757047","repostId":"1121308321","repostType":4,"repost":{"id":"1121308321","pubTimestamp":1628859436,"share":"https://ttm.financial/m/news/1121308321?lang=&edition=fundamental","pubTime":"2021-08-13 20:57","market":"us","language":"en","title":"Americans With Weak Immune Systems Will Get 3 Covid Shots","url":"https://stock-news.laohu8.com/highlight/detail?id=1121308321","media":"Bloomberg","summary":"Americans with weakened immune systems will be allowed to get three shots of Covid-19 vaccine after ","content":"<p>Americans with weakened immune systems will be allowed to get three shots of Covid-19 vaccine after U.S. regulators authorized giving an extra dose to the most vulnerable people.</p>\n<p>The U.S. Food and Drug Administration’s action expands the use of vaccines fromModerna Inc.and the partnership ofPfizer Inc.andBioNTech SEfor organ transplant recipients and patients with other conditions like cancer that hobble the body’s natural infection-fighting response. The decision doesn’t apply to other fully vaccinated individuals, the agency said in astatement.</p>\n<p>The U.S. is currently facing a surge of infections spawned by the highly infectious delta variant, with more than 117,000 new cases diagnosed yesterday. The FDA’s move was designed to protect those people most likely to be harmed or die from an infection, even after a standard course of shots.</p>\n<p>“The country has entered yet another wave of the Covid-19 pandemic, and the FDA is especially cognizant that immunocompromised people are particularly at risk for severe disease,” said Acting Commissioner Janet Woodcock. “After a thorough review of the available data, the FDA determined that this small, vulnerable group may benefit from a third dose of the Pfizer-BioNTech or Moderna vaccines.”</p>\n<p>Vaccine Access</p>\n<p>The decision could further exacerbate the vaccine inequality that exists across the world. The U.S. is joining countries including Israel, Germany and France in offering boosters to vulnerable groups, while nations including Russia and the United Arab Emirates are giving them even more broadly. The European Union’s drugs regulatorsaidFriday that it’s coordinating with vaccine makers and reviewing data on third shots.</p>\n<p>Meanwhile, dozens of countries have such limited access to the vaccines that they have immunized fewer than 10% of their populations.</p>\n<p>The FDA’s decision was supported by a study published in the New England Journal of Medicine on Wednesday, showing that a third dose of Moderna’s vaccine significantly raised levels of Covid-fighting antibodies in 55% of transplant patients. Among those who got a placebo rather than the extra shot, just 18% generated the desired antibody levels, thestudyfound.</p>\n<p>“Ifeelvery relieved that they are doing this, because it will save lives,” said Janet Handal, a kidney transplant recipient. “I wish that they had done it sooner.”</p>\n<p>While the U.S.-authorized Covid-19 vaccines are highly effective at preventing severe disease, hospitalization and death in most people, booster shots are especially important for transplant patients and others with weak immune systems, who often don’t get adequate responses to their first vaccine course. Immune compromised people compose about 3% of adults, Rochelle Walensky, director of the Centers for Disease Control and Prevention, said on a press call.</p>\n<p>Many patients had sought out extra doses on their own as findings emerged on their responses to vaccines. Dorry Segev, a professor of surgery and epidemiology at Johns Hopkins University, said his research team has observed more than 200 transplant recipients who have gotten third shots, and he suspects many more immunocompromised patients have done so as well.</p>\n<p>Advisers for the CDC raised concerns at a meeting last month about patients getting additional doses in an unsupervised manner and the inequities that could arise.</p>\n<p>“The people who’ve gotten it now are the people who navigate the health care system well, who are willing to go to great lengths,” Segev said. FDA approval “would then expand access of these boosters in a more equitable way to people who might not be as good as navigating the health care system and might have been too shy or too worried about pursuing something.”</p>\n<p>The FDA’s action allows for a third shot at least 28 days after the initial two-dose regimen in organ transplant recipients and patients with conditions “considered to have an equivalent level of immunocompromise.” Immune compromising conditions include blood cancers, HIV, multiple sclerosis and many others. In some cases, patients’ conditions weaken the immune system; in others, it’s their medications. Among the various conditions, the degree of immune suppression may differ.</p>\n<p>Not all patients may develop an antibody response after the third dose, as research so far has shown. Until there’s more information about how much protection patients have after a third dose and until the delta wave subsides, patients should still continue to mask and social distance, Segev said.</p>\n<p>Only those with weakened immune systems will be offered boosters, White House chief medical adviser Anthony Fauci said on NBC’s ”Today” show. For other vaccinated groups, such as the elderly, data is being collected to determine if or when their protection goes “below a critical level.”</p>\n<p>“Right now at this moment, other than the immune-compromised, we’re not going to be giving boosters to people, but we will be following them very carefully, and if they do need it, we’ll be ready to give it to them,” he said.</p>\n<p>About 60% of eligible Americans, age 12 and older, are fully vaccinated, according to the CDC. And while the pace of immunization is rising after falling sharply from a high point in mid-April, the Biden administration is urging people to get shots as infections surge in the U.S., fueled by the delta variant.</p>\n<p>An advisory committee to the CDC is also set to discuss booster doses of Covid–19 vaccine for immunocompromised patients on Friday.</p>\n<p>Handal and other transplant recipients formed Transplant Recipients and Immunocompromised Patient Advocacy Group during the pandemic that has urged the FDA to streamline approval of additional doses for those with weakened immune systems.</p>\n<p>“People that are immunocompromised are continuing to live with the fear that everyonefeltin the early days of Covid,” Handal said in an interview. They’re carrying on with their lives as the world opens up, but “it’s just an undercurrent of fear, and it’s exhausting to live with.”</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Americans With Weak Immune Systems Will Get 3 Covid Shots</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmericans With Weak Immune Systems Will Get 3 Covid Shots\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-13 20:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-13/u-s-clears-third-covid-shot-for-immunocompromised-patients><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Americans with weakened immune systems will be allowed to get three shots of Covid-19 vaccine after U.S. regulators authorized giving an extra dose to the most vulnerable people.\nThe U.S. Food and ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-13/u-s-clears-third-covid-shot-for-immunocompromised-patients\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-08-13/u-s-clears-third-covid-shot-for-immunocompromised-patients","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1121308321","content_text":"Americans with weakened immune systems will be allowed to get three shots of Covid-19 vaccine after U.S. regulators authorized giving an extra dose to the most vulnerable people.\nThe U.S. Food and Drug Administration’s action expands the use of vaccines fromModerna Inc.and the partnership ofPfizer Inc.andBioNTech SEfor organ transplant recipients and patients with other conditions like cancer that hobble the body’s natural infection-fighting response. The decision doesn’t apply to other fully vaccinated individuals, the agency said in astatement.\nThe U.S. is currently facing a surge of infections spawned by the highly infectious delta variant, with more than 117,000 new cases diagnosed yesterday. The FDA’s move was designed to protect those people most likely to be harmed or die from an infection, even after a standard course of shots.\n“The country has entered yet another wave of the Covid-19 pandemic, and the FDA is especially cognizant that immunocompromised people are particularly at risk for severe disease,” said Acting Commissioner Janet Woodcock. “After a thorough review of the available data, the FDA determined that this small, vulnerable group may benefit from a third dose of the Pfizer-BioNTech or Moderna vaccines.”\nVaccine Access\nThe decision could further exacerbate the vaccine inequality that exists across the world. The U.S. is joining countries including Israel, Germany and France in offering boosters to vulnerable groups, while nations including Russia and the United Arab Emirates are giving them even more broadly. The European Union’s drugs regulatorsaidFriday that it’s coordinating with vaccine makers and reviewing data on third shots.\nMeanwhile, dozens of countries have such limited access to the vaccines that they have immunized fewer than 10% of their populations.\nThe FDA’s decision was supported by a study published in the New England Journal of Medicine on Wednesday, showing that a third dose of Moderna’s vaccine significantly raised levels of Covid-fighting antibodies in 55% of transplant patients. Among those who got a placebo rather than the extra shot, just 18% generated the desired antibody levels, thestudyfound.\n“Ifeelvery relieved that they are doing this, because it will save lives,” said Janet Handal, a kidney transplant recipient. “I wish that they had done it sooner.”\nWhile the U.S.-authorized Covid-19 vaccines are highly effective at preventing severe disease, hospitalization and death in most people, booster shots are especially important for transplant patients and others with weak immune systems, who often don’t get adequate responses to their first vaccine course. Immune compromised people compose about 3% of adults, Rochelle Walensky, director of the Centers for Disease Control and Prevention, said on a press call.\nMany patients had sought out extra doses on their own as findings emerged on their responses to vaccines. Dorry Segev, a professor of surgery and epidemiology at Johns Hopkins University, said his research team has observed more than 200 transplant recipients who have gotten third shots, and he suspects many more immunocompromised patients have done so as well.\nAdvisers for the CDC raised concerns at a meeting last month about patients getting additional doses in an unsupervised manner and the inequities that could arise.\n“The people who’ve gotten it now are the people who navigate the health care system well, who are willing to go to great lengths,” Segev said. FDA approval “would then expand access of these boosters in a more equitable way to people who might not be as good as navigating the health care system and might have been too shy or too worried about pursuing something.”\nThe FDA’s action allows for a third shot at least 28 days after the initial two-dose regimen in organ transplant recipients and patients with conditions “considered to have an equivalent level of immunocompromise.” Immune compromising conditions include blood cancers, HIV, multiple sclerosis and many others. In some cases, patients’ conditions weaken the immune system; in others, it’s their medications. Among the various conditions, the degree of immune suppression may differ.\nNot all patients may develop an antibody response after the third dose, as research so far has shown. Until there’s more information about how much protection patients have after a third dose and until the delta wave subsides, patients should still continue to mask and social distance, Segev said.\nOnly those with weakened immune systems will be offered boosters, White House chief medical adviser Anthony Fauci said on NBC’s ”Today” show. For other vaccinated groups, such as the elderly, data is being collected to determine if or when their protection goes “below a critical level.”\n“Right now at this moment, other than the immune-compromised, we’re not going to be giving boosters to people, but we will be following them very carefully, and if they do need it, we’ll be ready to give it to them,” he said.\nAbout 60% of eligible Americans, age 12 and older, are fully vaccinated, according to the CDC. And while the pace of immunization is rising after falling sharply from a high point in mid-April, the Biden administration is urging people to get shots as infections surge in the U.S., fueled by the delta variant.\nAn advisory committee to the CDC is also set to discuss booster doses of Covid–19 vaccine for immunocompromised patients on Friday.\nHandal and other transplant recipients formed Transplant Recipients and Immunocompromised Patient Advocacy Group during the pandemic that has urged the FDA to streamline approval of additional doses for those with weakened immune systems.\n“People that are immunocompromised are continuing to live with the fear that everyonefeltin the early days of Covid,” Handal said in an interview. They’re carrying on with their lives as the world opens up, but “it’s just an undercurrent of fear, and it’s exhausting to live with.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":172,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":898252212,"gmtCreate":1628504123536,"gmtModify":1703507191536,"author":{"id":"3556954148323654","authorId":"3556954148323654","name":"cart158","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3556954148323654","authorIdStr":"3556954148323654"},"themes":[],"htmlText":"Think stock will go up?","listText":"Think stock will go up?","text":"Think stock will go up?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/898252212","repostId":"2158284412","repostType":2,"isVote":1,"tweetType":1,"viewCount":183,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":804769431,"gmtCreate":1627981064623,"gmtModify":1703499032102,"author":{"id":"3556954148323654","authorId":"3556954148323654","name":"cart158","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3556954148323654","authorIdStr":"3556954148323654"},"themes":[],"htmlText":"Hope time to buy the stock come","listText":"Hope time to buy the stock come","text":"Hope time to buy the stock come","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/804769431","repostId":"1104668581","repostType":4,"repost":{"id":"1104668581","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1627977934,"share":"https://ttm.financial/m/news/1104668581?lang=&edition=fundamental","pubTime":"2021-08-03 16:05","market":"us","language":"en","title":"Apple Will Have To Face Patent Infringement Lawsuit Over Apple Watch Heart Rate Sensor, Rules Court","url":"https://stock-news.laohu8.com/highlight/detail?id=1104668581","media":"Benzinga","summary":"Apple Inc. will have to face a patent infringement lawsuit over the heart rate sensor technology in ","content":"<p><b><a href=\"https://laohu8.com/S/AAPL\">Apple</a> Inc.</b>&nbsp;will have to face a patent infringement lawsuit over the heart rate sensor technology in the <a href=\"https://laohu8.com/S/AAPL\">Apple</a> Watch, AppleInsiderreportedMonday, citing a ruling by the U.S. Court of Appeals for the Federal Circuit.</p>\n<p><b>What Happened</b>: The original lawsuit - filed by&nbsp;<b>Omni MedSci Inc.</b>&nbsp;in 2018 - had alleged that Apple Watch’s heart rate measurement technology infringed on multiple patents owned by the company, as per the report.</p>\n<p>Apple’s move to get the lawsuit dismissed was denied by a U.S. District Court. The case was brought to the Federal Circuit after the<b>Tim Cook</b>-led company appealed the decision, the report noted.</p>\n<p>The patents were reportedly owned by University of Michigan professor&nbsp;<b>Mohammed Islam</b>, who later assigned the patent rights to Omni MedSci.</p>\n<p>However, Apple had argued that the patents actually belonged to the University of Michigan, citing Islam’s employment agreement with the university, as per the report. The federal circuit disagreed with the tech giant’s argument.</p>\n<p><b>Why It Matters:</b>&nbsp;Apple is facing other lawsuits too related to the Apple Watch.It wasreportedin May that privately-held medical device maker<b>AliveCor Inc.</b>filed a federal antitrust lawsuit against the Cupertino-based company, accusing it of monopolizing the market for heart-rate technology for the Apple Watch.</p>\n<p>The Apple Watch is an important product for Apple and is part of the company’s wearables, home, and accessories segment that generated sales of $8.78 billion in the recent third quarter, up 36% year-over-year.</p>\n<p><b>Price Action</b>: Apple shares closed 0.2% lower in Monday’s trading session at $145.52.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title> Apple Will Have To Face Patent Infringement Lawsuit Over Apple Watch Heart Rate Sensor, Rules Court</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n Apple Will Have To Face Patent Infringement Lawsuit Over Apple Watch Heart Rate Sensor, Rules Court\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-03 16:05</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b><a href=\"https://laohu8.com/S/AAPL\">Apple</a> Inc.</b>&nbsp;will have to face a patent infringement lawsuit over the heart rate sensor technology in the <a href=\"https://laohu8.com/S/AAPL\">Apple</a> Watch, AppleInsiderreportedMonday, citing a ruling by the U.S. Court of Appeals for the Federal Circuit.</p>\n<p><b>What Happened</b>: The original lawsuit - filed by&nbsp;<b>Omni MedSci Inc.</b>&nbsp;in 2018 - had alleged that Apple Watch’s heart rate measurement technology infringed on multiple patents owned by the company, as per the report.</p>\n<p>Apple’s move to get the lawsuit dismissed was denied by a U.S. District Court. The case was brought to the Federal Circuit after the<b>Tim Cook</b>-led company appealed the decision, the report noted.</p>\n<p>The patents were reportedly owned by University of Michigan professor&nbsp;<b>Mohammed Islam</b>, who later assigned the patent rights to Omni MedSci.</p>\n<p>However, Apple had argued that the patents actually belonged to the University of Michigan, citing Islam’s employment agreement with the university, as per the report. The federal circuit disagreed with the tech giant’s argument.</p>\n<p><b>Why It Matters:</b>&nbsp;Apple is facing other lawsuits too related to the Apple Watch.It wasreportedin May that privately-held medical device maker<b>AliveCor Inc.</b>filed a federal antitrust lawsuit against the Cupertino-based company, accusing it of monopolizing the market for heart-rate technology for the Apple Watch.</p>\n<p>The Apple Watch is an important product for Apple and is part of the company’s wearables, home, and accessories segment that generated sales of $8.78 billion in the recent third quarter, up 36% year-over-year.</p>\n<p><b>Price Action</b>: Apple shares closed 0.2% lower in Monday’s trading session at $145.52.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"03086":"华夏纳指","09086":"华夏纳指-U","AAPL":"苹果"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104668581","content_text":"Apple Inc. will have to face a patent infringement lawsuit over the heart rate sensor technology in the Apple Watch, AppleInsiderreportedMonday, citing a ruling by the U.S. Court of Appeals for the Federal Circuit.\nWhat Happened: The original lawsuit - filed by Omni MedSci Inc. in 2018 - had alleged that Apple Watch’s heart rate measurement technology infringed on multiple patents owned by the company, as per the report.\nApple’s move to get the lawsuit dismissed was denied by a U.S. District Court. The case was brought to the Federal Circuit after theTim Cook-led company appealed the decision, the report noted.\nThe patents were reportedly owned by University of Michigan professor Mohammed Islam, who later assigned the patent rights to Omni MedSci.\nHowever, Apple had argued that the patents actually belonged to the University of Michigan, citing Islam’s employment agreement with the university, as per the report. The federal circuit disagreed with the tech giant’s argument.\nWhy It Matters: Apple is facing other lawsuits too related to the Apple Watch.It wasreportedin May that privately-held medical device makerAliveCor Inc.filed a federal antitrust lawsuit against the Cupertino-based company, accusing it of monopolizing the market for heart-rate technology for the Apple Watch.\nThe Apple Watch is an important product for Apple and is part of the company’s wearables, home, and accessories segment that generated sales of $8.78 billion in the recent third quarter, up 36% year-over-year.\nPrice Action: Apple shares closed 0.2% lower in Monday’s trading session at $145.52.","news_type":1},"isVote":1,"tweetType":1,"viewCount":153,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":805072231,"gmtCreate":1627829678423,"gmtModify":1703496365242,"author":{"id":"3556954148323654","authorId":"3556954148323654","name":"cart158","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3556954148323654","authorIdStr":"3556954148323654"},"themes":[],"htmlText":"Hope it's become better","listText":"Hope it's become better","text":"Hope it's become better","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/805072231","repostId":"1138566016","repostType":4,"repost":{"id":"1138566016","pubTimestamp":1627689251,"share":"https://ttm.financial/m/news/1138566016?lang=&edition=fundamental","pubTime":"2021-07-31 07:54","market":"us","language":"en","title":"It’s Open Season on Closed-End Fund Activists. How Fund Holders Can Win—and Lose","url":"https://stock-news.laohu8.com/highlight/detail?id=1138566016","media":"Barron's","summary":"TheTempleton Global Incomefund frustrated investors for years. Despite star manager Michael Hasensta","content":"<p>TheTempleton Global Incomefund frustrated investors for years. Despite star manager Michael Hasenstab at the helm, the closed-end fund returned an average of 0.3% annually in the past decade, versus an average 7% for peers in global income. Also frustrating, its shares rarely traded close to the fund’s underlying net asset value, or NAV. The discount averaged 11% in the past three years.</p>\n<p>Investors have caught a break, however, thanks to Saba Capital Management, a hedge fund shop run by activist investor Boaz Weinstein. Saba amassed a 20% stake in the Templeton fund and recently won four contested board seats. It has been pressuring the board to take actions to boost the share price. Its moves have paid off: The fund has returned a total 4.5% this year as its share price improved, and the discount to NAV has shrunk to 4%.</p>\n<p>Tactics like Saba’s have long infuriated mutual fund companies; no one wants a hedge fund threatening a coup. Now, with some help from Congress, the playing field could tilt in favor of closed-end funds and their company sponsors, due to a bill recently introduced in the House. That could work against the interests of fund investors.</p>\n<p>The Increasing Investor Opportunities Act, introduced in June by Rep. Anthony Gonzalez (R., Ohio) and Rep. Gregory Meeks (D., New York), includes two measures that could make it much tougher for hedge funds to pressure closed-end funds and win proxy fights. One proposed change would lift the current 15% limit on closed-end-fund ownership of illiquid private funds, such as venture-capital and private-equity funds. A second measure would prevent activist hedge funds from acquiring more than 10% of a closed-end fund’s shares.</p>\n<p>A spokesman for Gonzalez declined to comment. Meeks didn’t respond to requests for comment.</p>\n<p>Proponents of the changes say they would expand access to private markets for retail investors. They also say hedge funds are exploiting gaps in securities laws at a cost to long-term shareholders, saddling them with tax liabilities, higher fees, and forced fund liquidations. The bill would eliminate a “loophole that activist investors have used to extract short-term profits at the expense of retail investors,” the Investment Company Institute, or ICI, said in a recent statement.</p>\n<p>Hedge funds and portfolio managers who invest in closed-end funds say that mutual fund companies are simply trying to protect a pool of assets and fees from shareholder interference. Most retail investors don’t vote their shares in proxy contests. That may leave fund boards largely free to pursue their own agendas.</p>\n<p>“Activism plays an important role, and if this bill passes, it will become more difficult for activists to threaten or create changes,” says Matt Buffington, a portfolio manager at Dryden Capital, an activist hedge fund.</p>\n<p>Gregory Neer, a portfolio manager with Relative Value Partners, an advisory firm that invests in closed-end funds, agrees. “The ability for investors to pressure funds is beneficial to all shareholders,” he says.</p>\n<p>Closed-end funds have long been popular with investors due to their high yields and steady distributions. Many use leverage, borrowing money at market rates to boost payouts. They also generate income with options strategies and investments in high-yielding areas of the stock and bond markets.</p>\n<p>But the funds have structural drawbacks. Expense ratios are steep, averaging 2.1%, according to Morningstar Direct. And since the funds have a fixed number of shares outstanding, prices reflect market demand for both a fund and its underlying assets. Funds usually trade at a discount to NAV. While it is attractive, in theory, to pay 90 cents for a dollar of assets, investors might never see the extra dime.</p>\n<p>Hedge funds aim to exploit this inefficiency, buying closed-end funds at below-market value. They then pressure fund boards to take steps to lift the funds’ prices. The playbook is straightforward: accumulate a stake, win board seats, and then force a fund company into a tender offer, whereby it agrees to repurchase shares at nearly full price.</p>\n<p>If that fails, a hedge fund might try to replace a fund’s manager, orchestrate a liquidation of the fund, or get it converted to an open-end fund—moves that could also pay off with the share price rising to parity with the NAV. Firms like Saba have also taken over funds entirely.</p>\n<p>Giving closed-end funds freedom to own more private securities could throw a wrench into the strategy. Tender offers work only if a fund can liquidate most of its holdings at market prices. Because venture-capital and private-equity holdings generally don’t trade publicly, their pricing isn’t transparent. “When closed-end funds invest in illiquid things, it protects them from activism,” one activist manager tells<i>Barron’s</i>.</p>\n<p>Removing the cap on private-fund ownership is “in line with a legislative agenda of getting retail investors more access to private investments,” says Thomas DeCapo, an attorney for the mutual fund industry.</p>\n<p>And capping activists at 10% of a fund doesn’t stop them from mounting proxy campaigns. “Nothing about this is antidemocratic,” he says. “It doesn’t stop a majority of investors who are unhappy or want change. It stops one investor from using its economic power, with other people’s money, to basically force changes on everybody else.”</p>\n<p>Investor advocates see it differently, however, saying fund investors could wind up paying higher fees for funds that hold more-opaque investments. “It’s just another fund-of-funds structure, and those are notoriously high-fee,” says Tyler Gellasch, head of Healthy Markets, an investor-protection group.</p>\n<p>Individual hedge funds technically can’t own more than 3% of a closed-end fund, under ownership restrictions in the Investment Company Act of 1940. But they skirt the rule by building stakes through affiliated entities, creating enough of a critical mass to force changes at a fund through proxy voting.</p>\n<p>The ICI—the mutual fund industry’s lobby—has tried to persuade regulators to crack down on hedge funds. In a submission to the Securities and Exchange Commission last year, the ICI argued that hedge fund campaigns often consume a fund’s resources, trigger tax liabilities for long-term investors, and result in the forced selling of securities to meet a hedge fund’s demands for a tender offer. A fund’s expense ratio could increase if it is forced to buy back shares and its asset base shrinks.</p>\n<p>The activist community’s “assault” on the industry has had a chilling effect on product launches, the ICI said, resulting in fewer closed-end funds on the market today than in 2007.</p>\n<p>But hedge funds argue that changing the 1940 act would amount to a power grab by mutual funds. “This is all coming from the mutual fund industry, and it’s no coincidence that this protects them,” says Phil Goldstein, co-founder of Bulldog Investors, an activist that has long targeted closed-end funds. “There are funds with terrible performance and wide discounts. The ICI never says we need a mechanism where shareholders can hold those managers accountable.”</p>\n<p>Imposing an ownership cap would also make proxy campaigns less economic. Limited to 10%, hedge funds wouldn’t own enough shares, with sufficient economic interest, to justify the expense of a proxy contest, which can cost millions of dollars. “If you’re limited to 10% and have to spend 2.5% of your assets on a proxy campaign, you’d say it’s too risky,” says Goldstein. “Meanwhile, management isn’t spending anything—just shareholder money. They want to make it economically unattractive to run a proxy contest.”</p>\n<p>Regulators and courts have expressed skepticism about some defenses that closed-end funds have adopted to prevent shareholder challenges. And, the SEC might not side with the fund industry. Since 2010, the SEC has warned fund companies against using state securities laws to thwart hedge fund takeovers. The SEC dropped its objection to these state “control share” laws last year under its Republican chairman, Jay Clayton. But the new, Democratic chairman, Gary Gensler, might reinstate the SEC’s objection—a reason for the industry to enlist Congress to change the law. The SEC didn’t respond to requests for comment.</p>\n<p>Institutional Shareholder Services,a firm that makes recommendations on proxy voting, says investors should reject fund companies’ use of state control-share laws, which limit the voting rights of shareholders. With the SEC on the sidelines, ISS says, “CEF shareholders are denied important voting rights and are subject to management entrenchment.”</p>\n<p><img src=\"https://static.tigerbbs.com/70323ed9daef142f19afd48be72b6299\" tg-width=\"755\" tg-height=\"334\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/68beb47d59eb02e90b04eb7093f9f17b\" tg-width=\"759\" tg-height=\"285\" referrerpolicy=\"no-referrer\">Hedge funds don’t always win, but investors might want to ride along as activists build a stake. “When an activist comes in, you usually see an increase in the share price and a decrease in the discount,” says Matt Souther, an associate finance professor at the University of South Carolina.</p>\n<p>Templeton Global Income’s (ticker: GIM) discount to NAV could narrow further if Saba acquires more shares or tries to take over the fund’s $743 million in assets. Saba recently took over management of another fund, Voya Prime Rate Trust, which it rebrandedSaba Capital Income &amp; Opportunities(BRW).Franklin Templetonand Saba declined to comment.</p>\n<p>Miller/Howard High Income Equity(HIE) is also in Saba’s crosshairs. The fund is a “term trust” with a mandated liquidation date in 2024. It trades at a 5.9% discount to NAV. “In a worst-case scenario, you buy it at a discount and you’ll earn an excess return from now to 2024 because that discount will narrow,” says Patrick Galley, co-manager ofRiverNorth Opportunities(RIV), a closed-end fund that owns HIE.</p>\n<p>Other closed-end funds in which Saba owns stakes includeSource Capital(SOR) andInvesco Dynamic Credit Opportunities(VTA). Bulldog has built a position inTortoise Energy Independence(NDP).</p>\n<p>Some closed-end funds look attractive on their fundamentals.Adams Diversified Equity(ADX) offers exposure to big tech stocks, trades at a 14% discount to NAV, and is committed to an annualized distribution of at least 6%. “For investors who expect tech to do well, ADX is a good holding,” says David Tepper, a closed-end investor and head of Tepper Capital Management in San Francisco.</p>\n<p>Sprott Focus Trust(FUND) is another fund he likes. Veteran small-cap manager Whitney George runs it, and his family owns 45% of the shares. It trades at a 10% discount and yields 5.7%. Tepper also favorsRoyce Global Value Trust(RGT), trading at a 9% discount and yielding 7.9%.</p>\n<p>None of these funds has attracted much activist involvement, according to securities filings. But if activists see opportunity, they could pile in and pressure fund management—assuming that Congress doesn’t rewrite the rules of engagement.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>It’s Open Season on Closed-End Fund Activists. How Fund Holders Can Win—and Lose</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIt’s Open Season on Closed-End Fund Activists. How Fund Holders Can Win—and Lose\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-31 07:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/congress-closed-end-funds-legislation-51627657959?mod=newsviewer_click><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>TheTempleton Global Incomefund frustrated investors for years. Despite star manager Michael Hasenstab at the helm, the closed-end fund returned an average of 0.3% annually in the past decade, versus ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/congress-closed-end-funds-legislation-51627657959?mod=newsviewer_click\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.marketwatch.com/articles/congress-closed-end-funds-legislation-51627657959?mod=newsviewer_click","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138566016","content_text":"TheTempleton Global Incomefund frustrated investors for years. Despite star manager Michael Hasenstab at the helm, the closed-end fund returned an average of 0.3% annually in the past decade, versus an average 7% for peers in global income. Also frustrating, its shares rarely traded close to the fund’s underlying net asset value, or NAV. The discount averaged 11% in the past three years.\nInvestors have caught a break, however, thanks to Saba Capital Management, a hedge fund shop run by activist investor Boaz Weinstein. Saba amassed a 20% stake in the Templeton fund and recently won four contested board seats. It has been pressuring the board to take actions to boost the share price. Its moves have paid off: The fund has returned a total 4.5% this year as its share price improved, and the discount to NAV has shrunk to 4%.\nTactics like Saba’s have long infuriated mutual fund companies; no one wants a hedge fund threatening a coup. Now, with some help from Congress, the playing field could tilt in favor of closed-end funds and their company sponsors, due to a bill recently introduced in the House. That could work against the interests of fund investors.\nThe Increasing Investor Opportunities Act, introduced in June by Rep. Anthony Gonzalez (R., Ohio) and Rep. Gregory Meeks (D., New York), includes two measures that could make it much tougher for hedge funds to pressure closed-end funds and win proxy fights. One proposed change would lift the current 15% limit on closed-end-fund ownership of illiquid private funds, such as venture-capital and private-equity funds. A second measure would prevent activist hedge funds from acquiring more than 10% of a closed-end fund’s shares.\nA spokesman for Gonzalez declined to comment. Meeks didn’t respond to requests for comment.\nProponents of the changes say they would expand access to private markets for retail investors. They also say hedge funds are exploiting gaps in securities laws at a cost to long-term shareholders, saddling them with tax liabilities, higher fees, and forced fund liquidations. The bill would eliminate a “loophole that activist investors have used to extract short-term profits at the expense of retail investors,” the Investment Company Institute, or ICI, said in a recent statement.\nHedge funds and portfolio managers who invest in closed-end funds say that mutual fund companies are simply trying to protect a pool of assets and fees from shareholder interference. Most retail investors don’t vote their shares in proxy contests. That may leave fund boards largely free to pursue their own agendas.\n“Activism plays an important role, and if this bill passes, it will become more difficult for activists to threaten or create changes,” says Matt Buffington, a portfolio manager at Dryden Capital, an activist hedge fund.\nGregory Neer, a portfolio manager with Relative Value Partners, an advisory firm that invests in closed-end funds, agrees. “The ability for investors to pressure funds is beneficial to all shareholders,” he says.\nClosed-end funds have long been popular with investors due to their high yields and steady distributions. Many use leverage, borrowing money at market rates to boost payouts. They also generate income with options strategies and investments in high-yielding areas of the stock and bond markets.\nBut the funds have structural drawbacks. Expense ratios are steep, averaging 2.1%, according to Morningstar Direct. And since the funds have a fixed number of shares outstanding, prices reflect market demand for both a fund and its underlying assets. Funds usually trade at a discount to NAV. While it is attractive, in theory, to pay 90 cents for a dollar of assets, investors might never see the extra dime.\nHedge funds aim to exploit this inefficiency, buying closed-end funds at below-market value. They then pressure fund boards to take steps to lift the funds’ prices. The playbook is straightforward: accumulate a stake, win board seats, and then force a fund company into a tender offer, whereby it agrees to repurchase shares at nearly full price.\nIf that fails, a hedge fund might try to replace a fund’s manager, orchestrate a liquidation of the fund, or get it converted to an open-end fund—moves that could also pay off with the share price rising to parity with the NAV. Firms like Saba have also taken over funds entirely.\nGiving closed-end funds freedom to own more private securities could throw a wrench into the strategy. Tender offers work only if a fund can liquidate most of its holdings at market prices. Because venture-capital and private-equity holdings generally don’t trade publicly, their pricing isn’t transparent. “When closed-end funds invest in illiquid things, it protects them from activism,” one activist manager tellsBarron’s.\nRemoving the cap on private-fund ownership is “in line with a legislative agenda of getting retail investors more access to private investments,” says Thomas DeCapo, an attorney for the mutual fund industry.\nAnd capping activists at 10% of a fund doesn’t stop them from mounting proxy campaigns. “Nothing about this is antidemocratic,” he says. “It doesn’t stop a majority of investors who are unhappy or want change. It stops one investor from using its economic power, with other people’s money, to basically force changes on everybody else.”\nInvestor advocates see it differently, however, saying fund investors could wind up paying higher fees for funds that hold more-opaque investments. “It’s just another fund-of-funds structure, and those are notoriously high-fee,” says Tyler Gellasch, head of Healthy Markets, an investor-protection group.\nIndividual hedge funds technically can’t own more than 3% of a closed-end fund, under ownership restrictions in the Investment Company Act of 1940. But they skirt the rule by building stakes through affiliated entities, creating enough of a critical mass to force changes at a fund through proxy voting.\nThe ICI—the mutual fund industry’s lobby—has tried to persuade regulators to crack down on hedge funds. In a submission to the Securities and Exchange Commission last year, the ICI argued that hedge fund campaigns often consume a fund’s resources, trigger tax liabilities for long-term investors, and result in the forced selling of securities to meet a hedge fund’s demands for a tender offer. A fund’s expense ratio could increase if it is forced to buy back shares and its asset base shrinks.\nThe activist community’s “assault” on the industry has had a chilling effect on product launches, the ICI said, resulting in fewer closed-end funds on the market today than in 2007.\nBut hedge funds argue that changing the 1940 act would amount to a power grab by mutual funds. “This is all coming from the mutual fund industry, and it’s no coincidence that this protects them,” says Phil Goldstein, co-founder of Bulldog Investors, an activist that has long targeted closed-end funds. “There are funds with terrible performance and wide discounts. The ICI never says we need a mechanism where shareholders can hold those managers accountable.”\nImposing an ownership cap would also make proxy campaigns less economic. Limited to 10%, hedge funds wouldn’t own enough shares, with sufficient economic interest, to justify the expense of a proxy contest, which can cost millions of dollars. “If you’re limited to 10% and have to spend 2.5% of your assets on a proxy campaign, you’d say it’s too risky,” says Goldstein. “Meanwhile, management isn’t spending anything—just shareholder money. They want to make it economically unattractive to run a proxy contest.”\nRegulators and courts have expressed skepticism about some defenses that closed-end funds have adopted to prevent shareholder challenges. And, the SEC might not side with the fund industry. Since 2010, the SEC has warned fund companies against using state securities laws to thwart hedge fund takeovers. The SEC dropped its objection to these state “control share” laws last year under its Republican chairman, Jay Clayton. But the new, Democratic chairman, Gary Gensler, might reinstate the SEC’s objection—a reason for the industry to enlist Congress to change the law. The SEC didn’t respond to requests for comment.\nInstitutional Shareholder Services,a firm that makes recommendations on proxy voting, says investors should reject fund companies’ use of state control-share laws, which limit the voting rights of shareholders. With the SEC on the sidelines, ISS says, “CEF shareholders are denied important voting rights and are subject to management entrenchment.”\nHedge funds don’t always win, but investors might want to ride along as activists build a stake. “When an activist comes in, you usually see an increase in the share price and a decrease in the discount,” says Matt Souther, an associate finance professor at the University of South Carolina.\nTempleton Global Income’s (ticker: GIM) discount to NAV could narrow further if Saba acquires more shares or tries to take over the fund’s $743 million in assets. Saba recently took over management of another fund, Voya Prime Rate Trust, which it rebrandedSaba Capital Income & Opportunities(BRW).Franklin Templetonand Saba declined to comment.\nMiller/Howard High Income Equity(HIE) is also in Saba’s crosshairs. The fund is a “term trust” with a mandated liquidation date in 2024. It trades at a 5.9% discount to NAV. “In a worst-case scenario, you buy it at a discount and you’ll earn an excess return from now to 2024 because that discount will narrow,” says Patrick Galley, co-manager ofRiverNorth Opportunities(RIV), a closed-end fund that owns HIE.\nOther closed-end funds in which Saba owns stakes includeSource Capital(SOR) andInvesco Dynamic Credit Opportunities(VTA). Bulldog has built a position inTortoise Energy Independence(NDP).\nSome closed-end funds look attractive on their fundamentals.Adams Diversified Equity(ADX) offers exposure to big tech stocks, trades at a 14% discount to NAV, and is committed to an annualized distribution of at least 6%. “For investors who expect tech to do well, ADX is a good holding,” says David Tepper, a closed-end investor and head of Tepper Capital Management in San Francisco.\nSprott Focus Trust(FUND) is another fund he likes. Veteran small-cap manager Whitney George runs it, and his family owns 45% of the shares. It trades at a 10% discount and yields 5.7%. Tepper also favorsRoyce Global Value Trust(RGT), trading at a 9% discount and yielding 7.9%.\nNone of these funds has attracted much activist involvement, according to securities filings. But if activists see opportunity, they could pile in and pressure fund management—assuming that Congress doesn’t rewrite the rules of engagement.","news_type":1},"isVote":1,"tweetType":1,"viewCount":244,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":880832797,"gmtCreate":1631029950319,"gmtModify":1676530448609,"author":{"id":"3556954148323654","authorId":"3556954148323654","name":"cart158","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3556954148323654","authorIdStr":"3556954148323654"},"themes":[],"htmlText":"But share today start drop wo","listText":"But share today start drop wo","text":"But share today start drop wo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/880832797","repostId":"2165849354","repostType":4,"repost":{"id":"2165849354","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1631027520,"share":"https://ttm.financial/m/news/2165849354?lang=&edition=fundamental","pubTime":"2021-09-07 23:12","market":"us","language":"en","title":"Wall Street sees as much as 56% upside for its 20 favorite stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2165849354","media":"Dow Jones","summary":"Stocks favored by analysts include Micron, GM, Activision Blizzard and Southwest Airlines.\n\nAs the s","content":"<blockquote>\n Stocks favored by analysts include Micron, GM, Activision Blizzard and Southwest Airlines.\n</blockquote>\n<p>As the stock market reopens following Labor Day weekend, there is no shortage of warnings that a correction is due -- which would be a pullback of at least 10% for the benchmark S&amp;P 500 following a gain of 21% so far this year.</p>\n<p>But there still may be catalysts for stock prices as the economy rebounds and interest rates remain low. A list of favorite S&amp;P 500 stocks among Wall Street analysts is below.</p>\n<p>In Monday's Need to Know column, Barbara Kollmeyer cites Matt Maley, chief market strategist at Miller Tabak + Co., who sees parallels between current market conditions and those of 2007, 1999 and 1929 that preceded three crashes.</p>\n<p>Then again, John Buckingham, editor of the Prudent Speculator newsletter, shared this chart, which shows how the market recovered after declines brought about by 20 \"frightening events\" going back to 2010:</p>\n<p>An investor with a crystal ball might time the market perfectly, selling everything at a market top and buying at the bottom. But the human tendency, even for an investor who \"gets out in time,\" is to buy back in too late and miss the rebound. For the vast majority of long-term investors, waiting out a bear market (<a href=\"https://laohu8.com/S/AONE.U\">one</a> with a decline of at least 20%) tends to work out well if one can stay in for three years. If your investment horizon is shorter than that, stocks might not be for you.</p>\n<p>Buckingham's chart, above, shows how well the S&amp;P 500 has performed since the COVID-19 crisis began. But here's another way of illustrating how quickly the market can recover, especially when supported by government stimulus and Federal Reserve policy -- the S&amp;P 500's price movement since the end of 2019:</p>\n<p>From an intraday peak Feb. 10, 2020, through the pandemic trough March 23, 2020, the S&amp;P 500 dropped 35%. It has gained 107% since that bottom. But if you look more closely, you can see significant pullbacks (based on intraday prices) of 11% between Sept. 2, 2020, and Sept. 24, 2020, and 9% between Oct. 10, 2020, and Oct. 30, 2020. Those weren't fun periods for investors, but in hindsight they were blips. Investors fare best when they held on.</p>\n<p><b>Valuations and relative bargains</b></p>\n<p>Federal stimulus and central-bank easy-money policies have made interest rates so low that some investors who would traditionally lean toward bonds and preferred stocks for income turned toward common stocks. So the forward price-to-earnings (P/E) ratio for the S&amp;P 500 is now 21.4, based on consensus estimates among analysts polled by FactSet, compared to a 10-year average valuation of 16.5.</p>\n<p>The 11 sectors of the S&amp;P 500 tend to trade higher or lower than the full index on a P/E basis. Here are the sectors' relative valuations to the full index and how those compare to average valuations:</p>\n<table>\n <tbody>\n  <tr>\n   <td>S&amp;P 500 sector</td>\n   <td>Forward P/E</td>\n   <td>Average forward P/E -- 10 years</td>\n   <td>P/E to full index P/E</td>\n   <td>Average P/E to average full index P/E</td>\n   <td>Relative premium or discount</td>\n  </tr>\n  <tr>\n   <td>Energy</td>\n   <td>13.2</td>\n   <td>15.3</td>\n   <td>62%</td>\n   <td>93%</td>\n   <td>-31%</td>\n  </tr>\n  <tr>\n   <td>Materials</td>\n   <td>17.2</td>\n   <td>15.8</td>\n   <td>80%</td>\n   <td>95%</td>\n   <td>-15%</td>\n  </tr>\n  <tr>\n   <td>Industrials</td>\n   <td>22.5</td>\n   <td>16.7</td>\n   <td>105%</td>\n   <td>101%</td>\n   <td>4%</td>\n  </tr>\n  <tr>\n   <td>Consumer Discretionary</td>\n   <td>31.5</td>\n   <td>22.1</td>\n   <td>148%</td>\n   <td>134%</td>\n   <td>14%</td>\n  </tr>\n  <tr>\n   <td>Consumer Staples</td>\n   <td>20.8</td>\n   <td>18.5</td>\n   <td>97%</td>\n   <td>112%</td>\n   <td>-15%</td>\n  </tr>\n  <tr>\n   <td>Health Care</td>\n   <td>17.7</td>\n   <td>15.5</td>\n   <td>83%</td>\n   <td>94%</td>\n   <td>-11%</td>\n  </tr>\n  <tr>\n   <td>Financials</td>\n   <td>14.4</td>\n   <td>12.2</td>\n   <td>67%</td>\n   <td>74%</td>\n   <td>-7%</td>\n  </tr>\n  <tr>\n   <td>Real Estate</td>\n   <td>23.3</td>\n   <td>18.6</td>\n   <td>109%</td>\n   <td>112%</td>\n   <td>-3%</td>\n  </tr>\n  <tr>\n   <td>Information Technology</td>\n   <td>26.6</td>\n   <td>16.8</td>\n   <td>125%</td>\n   <td>102%</td>\n   <td>23%</td>\n  </tr>\n  <tr>\n   <td>Communication Services</td>\n   <td>22.7</td>\n   <td>18.6</td>\n   <td>106%</td>\n   <td>113%</td>\n   <td>-6%</td>\n  </tr>\n  <tr>\n   <td>Utilities</td>\n   <td>20.0</td>\n   <td>16.7</td>\n   <td>94%</td>\n   <td>101%</td>\n   <td>-7%</td>\n  </tr>\n  <tr>\n   <td>S&amp;P 500</td>\n   <td>21.4</td>\n   <td>16.5</td>\n   <td></td>\n   <td></td>\n   <td></td>\n  </tr>\n  <tr>\n   <td>Source: FactSet</td>\n   <td></td>\n   <td></td>\n   <td></td>\n   <td></td>\n   <td></td>\n  </tr>\n </tbody>\n</table>\n<p>It probably isn't a surprise to see that the information technology sector, dominated by rapidly growing tech giants (in an index weighted by market capitalization) trades much higher relative to the full index than it did five years ago, or that the energy sector trades much lower.</p>\n<p>But it is worth noting that several sectors still trade lower than usual, relative to the full index, even in a market that has lifted 88% of the S&amp;P 500 this year. These include health care, which is up 20% in 2021, and the financial sector, up 29%.</p>\n<p><b>Wall Street's favorites among the S&amp;P 500</b></p>\n<p>Analysts who work for brokerage firms tend to shy away from negative ratings. Among the S&amp;P 500, there are no companies with majority \"sell\" or equivalent ratings. But the analysts still have clear preferences for some stocks over others. Here are 20 stocks in the benchmark index with at least 75% \"buy\" or equivalent ratings, with the most upside implied for the next year, based on consensus price targets:</p>\n<table>\n <tbody>\n  <tr>\n   <td>Company</td>\n   <td>Share \"buy\" ratings</td>\n   <td>Closing price -- Sept. 3</td>\n   <td>Consensus price target</td>\n   <td>Implied 12-month upside potential</td>\n  </tr>\n  <tr>\n   <td>Micron Technology Inc. MU</td>\n   <td>88%</td>\n   <td>$73.81</td>\n   <td>$114.96</td>\n   <td>56%</td>\n  </tr>\n  <tr>\n   <td><a href=\"https://laohu8.com/S/FANG\">Diamondback Energy</a> Inc. FANG</td>\n   <td>91%</td>\n   <td>$75.56</td>\n   <td>$113.52</td>\n   <td>50%</td>\n  </tr>\n  <tr>\n   <td>General Motors Co. GM</td>\n   <td>92%</td>\n   <td>$48.82</td>\n   <td>$72.16</td>\n   <td>48%</td>\n  </tr>\n  <tr>\n   <td><a href=\"https://laohu8.com/S/NWSAL\">News Corp</a>. Class A NWSA</td>\n   <td>80%</td>\n   <td>$22.56</td>\n   <td>$32.74</td>\n   <td>45%</td>\n  </tr>\n  <tr>\n   <td>Global Payments Inc. GPN</td>\n   <td>81%</td>\n   <td>$158.01</td>\n   <td>$228.69</td>\n   <td>45%</td>\n  </tr>\n  <tr>\n   <td>Activision Blizzard Inc. ATVI</td>\n   <td>91%</td>\n   <td>$81.18</td>\n   <td>$116.04</td>\n   <td>43%</td>\n  </tr>\n  <tr>\n   <td>Alaska Air Group Inc. ALK</td>\n   <td>93%</td>\n   <td>$57.11</td>\n   <td>$80.00</td>\n   <td>40%</td>\n  </tr>\n  <tr>\n   <td>Pioneer Natural Resources Co. PXD</td>\n   <td>81%</td>\n   <td>$149.88</td>\n   <td>$207.09</td>\n   <td>38%</td>\n  </tr>\n  <tr>\n   <td>Southwest Airlines Co. LUV</td>\n   <td>82%</td>\n   <td>$48.86</td>\n   <td>$66.24</td>\n   <td>36%</td>\n  </tr>\n  <tr>\n   <td>Lamb Weston Holdings Inc. LW</td>\n   <td>78%</td>\n   <td>$63.58</td>\n   <td>$85.43</td>\n   <td>34%</td>\n  </tr>\n  <tr>\n   <td>ConocoPhillips COP</td>\n   <td>97%</td>\n   <td>$56.24</td>\n   <td>$75.52</td>\n   <td>34%</td>\n  </tr>\n  <tr>\n   <td><a href=\"https://laohu8.com/S/CNC\">Centene Corp</a>. CNC</td>\n   <td>85%</td>\n   <td>$64.37</td>\n   <td>$85.47</td>\n   <td>33%</td>\n  </tr>\n  <tr>\n   <td>Vertex Pharmaceuticals Inc. VRTX</td>\n   <td>78%</td>\n   <td>$198.05</td>\n   <td>$262.14</td>\n   <td>32%</td>\n  </tr>\n  <tr>\n   <td>FedEx Corp. FDX</td>\n   <td>78%</td>\n   <td>$266.04</td>\n   <td>$349.48</td>\n   <td>31%</td>\n  </tr>\n  <tr>\n   <td>Devon Energy Corp. DVN</td>\n   <td>85%</td>\n   <td>$29.17</td>\n   <td>$38.19</td>\n   <td>31%</td>\n  </tr>\n  <tr>\n   <td>Valero Energy Corp. VLO</td>\n   <td>85%</td>\n   <td>$64.70</td>\n   <td>$84.06</td>\n   <td>30%</td>\n  </tr>\n  <tr>\n   <td>Mastercard Inc. Class A MA</td>\n   <td>84%</td>\n   <td>$340.23</td>\n   <td>$439.16</td>\n   <td>29%</td>\n  </tr>\n  <tr>\n   <td><a href=\"https://laohu8.com/S/ZBH\">Zimmer Biomet Holdings Inc</a>. ZBH</td>\n   <td>79%</td>\n   <td>$146.74</td>\n   <td>$187.58</td>\n   <td>28%</td>\n  </tr>\n  <tr>\n   <td>Schlumberger Ltd. SLB</td>\n   <td>79%</td>\n   <td>$28.09</td>\n   <td>$35.56</td>\n   <td>27%</td>\n  </tr>\n  <tr>\n   <td><a href=\"https://laohu8.com/S/TMUSR\">T-Mobile US Inc</a>. TMUS</td>\n   <td>87%</td>\n   <td>$136.00</td>\n   <td>$172.00</td>\n   <td>26%</td>\n  </tr>\n  <tr>\n   <td>Source: FactSet</td>\n   <td></td>\n   <td></td>\n   <td></td>\n   <td></td>\n  </tr>\n </tbody>\n</table>\n<p>Click on the tickers for more about each company.</p>\n<p>If you see any stocks of interest, you should do your own research and form your own opinion about how likely a company is to remain competitive over the next decade. Tomi Kilgore has just written a detailed guide to the information available on MarketWatch's quote page. That's a great way to begin digging into any stock.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street sees as much as 56% upside for its 20 favorite stocks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street sees as much as 56% upside for its 20 favorite stocks\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-09-07 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<blockquote>\n Stocks favored by analysts include Micron, GM, Activision Blizzard and Southwest Airlines.\n</blockquote>\n<p>As the stock market reopens following Labor Day weekend, there is no shortage of warnings that a correction is due -- which would be a pullback of at least 10% for the benchmark S&amp;P 500 following a gain of 21% so far this year.</p>\n<p>But there still may be catalysts for stock prices as the economy rebounds and interest rates remain low. A list of favorite S&amp;P 500 stocks among Wall Street analysts is below.</p>\n<p>In Monday's Need to Know column, Barbara Kollmeyer cites Matt Maley, chief market strategist at Miller Tabak + Co., who sees parallels between current market conditions and those of 2007, 1999 and 1929 that preceded three crashes.</p>\n<p>Then again, John Buckingham, editor of the Prudent Speculator newsletter, shared this chart, which shows how the market recovered after declines brought about by 20 \"frightening events\" going back to 2010:</p>\n<p>An investor with a crystal ball might time the market perfectly, selling everything at a market top and buying at the bottom. But the human tendency, even for an investor who \"gets out in time,\" is to buy back in too late and miss the rebound. For the vast majority of long-term investors, waiting out a bear market (<a href=\"https://laohu8.com/S/AONE.U\">one</a> with a decline of at least 20%) tends to work out well if one can stay in for three years. If your investment horizon is shorter than that, stocks might not be for you.</p>\n<p>Buckingham's chart, above, shows how well the S&amp;P 500 has performed since the COVID-19 crisis began. But here's another way of illustrating how quickly the market can recover, especially when supported by government stimulus and Federal Reserve policy -- the S&amp;P 500's price movement since the end of 2019:</p>\n<p>From an intraday peak Feb. 10, 2020, through the pandemic trough March 23, 2020, the S&amp;P 500 dropped 35%. It has gained 107% since that bottom. But if you look more closely, you can see significant pullbacks (based on intraday prices) of 11% between Sept. 2, 2020, and Sept. 24, 2020, and 9% between Oct. 10, 2020, and Oct. 30, 2020. Those weren't fun periods for investors, but in hindsight they were blips. Investors fare best when they held on.</p>\n<p><b>Valuations and relative bargains</b></p>\n<p>Federal stimulus and central-bank easy-money policies have made interest rates so low that some investors who would traditionally lean toward bonds and preferred stocks for income turned toward common stocks. So the forward price-to-earnings (P/E) ratio for the S&amp;P 500 is now 21.4, based on consensus estimates among analysts polled by FactSet, compared to a 10-year average valuation of 16.5.</p>\n<p>The 11 sectors of the S&amp;P 500 tend to trade higher or lower than the full index on a P/E basis. Here are the sectors' relative valuations to the full index and how those compare to average valuations:</p>\n<table>\n <tbody>\n  <tr>\n   <td>S&amp;P 500 sector</td>\n   <td>Forward P/E</td>\n   <td>Average forward P/E -- 10 years</td>\n   <td>P/E to full index P/E</td>\n   <td>Average P/E to average full index P/E</td>\n   <td>Relative premium or discount</td>\n  </tr>\n  <tr>\n   <td>Energy</td>\n   <td>13.2</td>\n   <td>15.3</td>\n   <td>62%</td>\n   <td>93%</td>\n   <td>-31%</td>\n  </tr>\n  <tr>\n   <td>Materials</td>\n   <td>17.2</td>\n   <td>15.8</td>\n   <td>80%</td>\n   <td>95%</td>\n   <td>-15%</td>\n  </tr>\n  <tr>\n   <td>Industrials</td>\n   <td>22.5</td>\n   <td>16.7</td>\n   <td>105%</td>\n   <td>101%</td>\n   <td>4%</td>\n  </tr>\n  <tr>\n   <td>Consumer Discretionary</td>\n   <td>31.5</td>\n   <td>22.1</td>\n   <td>148%</td>\n   <td>134%</td>\n   <td>14%</td>\n  </tr>\n  <tr>\n   <td>Consumer Staples</td>\n   <td>20.8</td>\n   <td>18.5</td>\n   <td>97%</td>\n   <td>112%</td>\n   <td>-15%</td>\n  </tr>\n  <tr>\n   <td>Health Care</td>\n   <td>17.7</td>\n   <td>15.5</td>\n   <td>83%</td>\n   <td>94%</td>\n   <td>-11%</td>\n  </tr>\n  <tr>\n   <td>Financials</td>\n   <td>14.4</td>\n   <td>12.2</td>\n   <td>67%</td>\n   <td>74%</td>\n   <td>-7%</td>\n  </tr>\n  <tr>\n   <td>Real Estate</td>\n   <td>23.3</td>\n   <td>18.6</td>\n   <td>109%</td>\n   <td>112%</td>\n   <td>-3%</td>\n  </tr>\n  <tr>\n   <td>Information Technology</td>\n   <td>26.6</td>\n   <td>16.8</td>\n   <td>125%</td>\n   <td>102%</td>\n   <td>23%</td>\n  </tr>\n  <tr>\n   <td>Communication Services</td>\n   <td>22.7</td>\n   <td>18.6</td>\n   <td>106%</td>\n   <td>113%</td>\n   <td>-6%</td>\n  </tr>\n  <tr>\n   <td>Utilities</td>\n   <td>20.0</td>\n   <td>16.7</td>\n   <td>94%</td>\n   <td>101%</td>\n   <td>-7%</td>\n  </tr>\n  <tr>\n   <td>S&amp;P 500</td>\n   <td>21.4</td>\n   <td>16.5</td>\n   <td></td>\n   <td></td>\n   <td></td>\n  </tr>\n  <tr>\n   <td>Source: FactSet</td>\n   <td></td>\n   <td></td>\n   <td></td>\n   <td></td>\n   <td></td>\n  </tr>\n </tbody>\n</table>\n<p>It probably isn't a surprise to see that the information technology sector, dominated by rapidly growing tech giants (in an index weighted by market capitalization) trades much higher relative to the full index than it did five years ago, or that the energy sector trades much lower.</p>\n<p>But it is worth noting that several sectors still trade lower than usual, relative to the full index, even in a market that has lifted 88% of the S&amp;P 500 this year. These include health care, which is up 20% in 2021, and the financial sector, up 29%.</p>\n<p><b>Wall Street's favorites among the S&amp;P 500</b></p>\n<p>Analysts who work for brokerage firms tend to shy away from negative ratings. Among the S&amp;P 500, there are no companies with majority \"sell\" or equivalent ratings. But the analysts still have clear preferences for some stocks over others. Here are 20 stocks in the benchmark index with at least 75% \"buy\" or equivalent ratings, with the most upside implied for the next year, based on consensus price targets:</p>\n<table>\n <tbody>\n  <tr>\n   <td>Company</td>\n   <td>Share \"buy\" ratings</td>\n   <td>Closing price -- Sept. 3</td>\n   <td>Consensus price target</td>\n   <td>Implied 12-month upside potential</td>\n  </tr>\n  <tr>\n   <td>Micron Technology Inc. MU</td>\n   <td>88%</td>\n   <td>$73.81</td>\n   <td>$114.96</td>\n   <td>56%</td>\n  </tr>\n  <tr>\n   <td><a href=\"https://laohu8.com/S/FANG\">Diamondback Energy</a> Inc. FANG</td>\n   <td>91%</td>\n   <td>$75.56</td>\n   <td>$113.52</td>\n   <td>50%</td>\n  </tr>\n  <tr>\n   <td>General Motors Co. GM</td>\n   <td>92%</td>\n   <td>$48.82</td>\n   <td>$72.16</td>\n   <td>48%</td>\n  </tr>\n  <tr>\n   <td><a href=\"https://laohu8.com/S/NWSAL\">News Corp</a>. Class A NWSA</td>\n   <td>80%</td>\n   <td>$22.56</td>\n   <td>$32.74</td>\n   <td>45%</td>\n  </tr>\n  <tr>\n   <td>Global Payments Inc. GPN</td>\n   <td>81%</td>\n   <td>$158.01</td>\n   <td>$228.69</td>\n   <td>45%</td>\n  </tr>\n  <tr>\n   <td>Activision Blizzard Inc. ATVI</td>\n   <td>91%</td>\n   <td>$81.18</td>\n   <td>$116.04</td>\n   <td>43%</td>\n  </tr>\n  <tr>\n   <td>Alaska Air Group Inc. ALK</td>\n   <td>93%</td>\n   <td>$57.11</td>\n   <td>$80.00</td>\n   <td>40%</td>\n  </tr>\n  <tr>\n   <td>Pioneer Natural Resources Co. PXD</td>\n   <td>81%</td>\n   <td>$149.88</td>\n   <td>$207.09</td>\n   <td>38%</td>\n  </tr>\n  <tr>\n   <td>Southwest Airlines Co. LUV</td>\n   <td>82%</td>\n   <td>$48.86</td>\n   <td>$66.24</td>\n   <td>36%</td>\n  </tr>\n  <tr>\n   <td>Lamb Weston Holdings Inc. LW</td>\n   <td>78%</td>\n   <td>$63.58</td>\n   <td>$85.43</td>\n   <td>34%</td>\n  </tr>\n  <tr>\n   <td>ConocoPhillips COP</td>\n   <td>97%</td>\n   <td>$56.24</td>\n   <td>$75.52</td>\n   <td>34%</td>\n  </tr>\n  <tr>\n   <td><a href=\"https://laohu8.com/S/CNC\">Centene Corp</a>. CNC</td>\n   <td>85%</td>\n   <td>$64.37</td>\n   <td>$85.47</td>\n   <td>33%</td>\n  </tr>\n  <tr>\n   <td>Vertex Pharmaceuticals Inc. VRTX</td>\n   <td>78%</td>\n   <td>$198.05</td>\n   <td>$262.14</td>\n   <td>32%</td>\n  </tr>\n  <tr>\n   <td>FedEx Corp. FDX</td>\n   <td>78%</td>\n   <td>$266.04</td>\n   <td>$349.48</td>\n   <td>31%</td>\n  </tr>\n  <tr>\n   <td>Devon Energy Corp. DVN</td>\n   <td>85%</td>\n   <td>$29.17</td>\n   <td>$38.19</td>\n   <td>31%</td>\n  </tr>\n  <tr>\n   <td>Valero Energy Corp. VLO</td>\n   <td>85%</td>\n   <td>$64.70</td>\n   <td>$84.06</td>\n   <td>30%</td>\n  </tr>\n  <tr>\n   <td>Mastercard Inc. Class A MA</td>\n   <td>84%</td>\n   <td>$340.23</td>\n   <td>$439.16</td>\n   <td>29%</td>\n  </tr>\n  <tr>\n   <td><a href=\"https://laohu8.com/S/ZBH\">Zimmer Biomet Holdings Inc</a>. ZBH</td>\n   <td>79%</td>\n   <td>$146.74</td>\n   <td>$187.58</td>\n   <td>28%</td>\n  </tr>\n  <tr>\n   <td>Schlumberger Ltd. SLB</td>\n   <td>79%</td>\n   <td>$28.09</td>\n   <td>$35.56</td>\n   <td>27%</td>\n  </tr>\n  <tr>\n   <td><a href=\"https://laohu8.com/S/TMUSR\">T-Mobile US Inc</a>. TMUS</td>\n   <td>87%</td>\n   <td>$136.00</td>\n   <td>$172.00</td>\n   <td>26%</td>\n  </tr>\n  <tr>\n   <td>Source: FactSet</td>\n   <td></td>\n   <td></td>\n   <td></td>\n   <td></td>\n  </tr>\n </tbody>\n</table>\n<p>Click on the tickers for more about each company.</p>\n<p>If you see any stocks of interest, you should do your own research and form your own opinion about how likely a company is to remain competitive over the next decade. Tomi Kilgore has just written a detailed guide to the information available on MarketWatch's quote page. That's a great way to begin digging into any stock.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","TERN":"Terns Pharmaceuticals, Inc.","GM":"通用汽车","SPXU":"三倍做空标普500ETF","MU":"美光科技",".SPX":"S&P 500 Index","SPY":"标普500ETF","OEX":"标普100","CRCT":"Cricut, Inc.","SDS":"两倍做空标普500ETF","OEF":"标普100指数ETF-iShares","ATVI":"动视暴雪","LUV":"西南航空","IVV":"标普500指数ETF","SLB":"斯伦贝谢","SH":"标普500反向ETF","UPRO":"三倍做多标普500ETF","SSO":"两倍做多标普500ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2165849354","content_text":"Stocks favored by analysts include Micron, GM, Activision Blizzard and Southwest Airlines.\n\nAs the stock market reopens following Labor Day weekend, there is no shortage of warnings that a correction is due -- which would be a pullback of at least 10% for the benchmark S&P 500 following a gain of 21% so far this year.\nBut there still may be catalysts for stock prices as the economy rebounds and interest rates remain low. A list of favorite S&P 500 stocks among Wall Street analysts is below.\nIn Monday's Need to Know column, Barbara Kollmeyer cites Matt Maley, chief market strategist at Miller Tabak + Co., who sees parallels between current market conditions and those of 2007, 1999 and 1929 that preceded three crashes.\nThen again, John Buckingham, editor of the Prudent Speculator newsletter, shared this chart, which shows how the market recovered after declines brought about by 20 \"frightening events\" going back to 2010:\nAn investor with a crystal ball might time the market perfectly, selling everything at a market top and buying at the bottom. But the human tendency, even for an investor who \"gets out in time,\" is to buy back in too late and miss the rebound. For the vast majority of long-term investors, waiting out a bear market (one with a decline of at least 20%) tends to work out well if one can stay in for three years. If your investment horizon is shorter than that, stocks might not be for you.\nBuckingham's chart, above, shows how well the S&P 500 has performed since the COVID-19 crisis began. But here's another way of illustrating how quickly the market can recover, especially when supported by government stimulus and Federal Reserve policy -- the S&P 500's price movement since the end of 2019:\nFrom an intraday peak Feb. 10, 2020, through the pandemic trough March 23, 2020, the S&P 500 dropped 35%. It has gained 107% since that bottom. But if you look more closely, you can see significant pullbacks (based on intraday prices) of 11% between Sept. 2, 2020, and Sept. 24, 2020, and 9% between Oct. 10, 2020, and Oct. 30, 2020. Those weren't fun periods for investors, but in hindsight they were blips. Investors fare best when they held on.\nValuations and relative bargains\nFederal stimulus and central-bank easy-money policies have made interest rates so low that some investors who would traditionally lean toward bonds and preferred stocks for income turned toward common stocks. So the forward price-to-earnings (P/E) ratio for the S&P 500 is now 21.4, based on consensus estimates among analysts polled by FactSet, compared to a 10-year average valuation of 16.5.\nThe 11 sectors of the S&P 500 tend to trade higher or lower than the full index on a P/E basis. Here are the sectors' relative valuations to the full index and how those compare to average valuations:\n\n\n\nS&P 500 sector\nForward P/E\nAverage forward P/E -- 10 years\nP/E to full index P/E\nAverage P/E to average full index P/E\nRelative premium or discount\n\n\nEnergy\n13.2\n15.3\n62%\n93%\n-31%\n\n\nMaterials\n17.2\n15.8\n80%\n95%\n-15%\n\n\nIndustrials\n22.5\n16.7\n105%\n101%\n4%\n\n\nConsumer Discretionary\n31.5\n22.1\n148%\n134%\n14%\n\n\nConsumer Staples\n20.8\n18.5\n97%\n112%\n-15%\n\n\nHealth Care\n17.7\n15.5\n83%\n94%\n-11%\n\n\nFinancials\n14.4\n12.2\n67%\n74%\n-7%\n\n\nReal Estate\n23.3\n18.6\n109%\n112%\n-3%\n\n\nInformation Technology\n26.6\n16.8\n125%\n102%\n23%\n\n\nCommunication Services\n22.7\n18.6\n106%\n113%\n-6%\n\n\nUtilities\n20.0\n16.7\n94%\n101%\n-7%\n\n\nS&P 500\n21.4\n16.5\n\n\n\n\n\nSource: FactSet\n\n\n\n\n\n\n\n\nIt probably isn't a surprise to see that the information technology sector, dominated by rapidly growing tech giants (in an index weighted by market capitalization) trades much higher relative to the full index than it did five years ago, or that the energy sector trades much lower.\nBut it is worth noting that several sectors still trade lower than usual, relative to the full index, even in a market that has lifted 88% of the S&P 500 this year. These include health care, which is up 20% in 2021, and the financial sector, up 29%.\nWall Street's favorites among the S&P 500\nAnalysts who work for brokerage firms tend to shy away from negative ratings. Among the S&P 500, there are no companies with majority \"sell\" or equivalent ratings. But the analysts still have clear preferences for some stocks over others. Here are 20 stocks in the benchmark index with at least 75% \"buy\" or equivalent ratings, with the most upside implied for the next year, based on consensus price targets:\n\n\n\nCompany\nShare \"buy\" ratings\nClosing price -- Sept. 3\nConsensus price target\nImplied 12-month upside potential\n\n\nMicron Technology Inc. MU\n88%\n$73.81\n$114.96\n56%\n\n\nDiamondback Energy Inc. FANG\n91%\n$75.56\n$113.52\n50%\n\n\nGeneral Motors Co. GM\n92%\n$48.82\n$72.16\n48%\n\n\nNews Corp. Class A NWSA\n80%\n$22.56\n$32.74\n45%\n\n\nGlobal Payments Inc. GPN\n81%\n$158.01\n$228.69\n45%\n\n\nActivision Blizzard Inc. ATVI\n91%\n$81.18\n$116.04\n43%\n\n\nAlaska Air Group Inc. ALK\n93%\n$57.11\n$80.00\n40%\n\n\nPioneer Natural Resources Co. PXD\n81%\n$149.88\n$207.09\n38%\n\n\nSouthwest Airlines Co. LUV\n82%\n$48.86\n$66.24\n36%\n\n\nLamb Weston Holdings Inc. LW\n78%\n$63.58\n$85.43\n34%\n\n\nConocoPhillips COP\n97%\n$56.24\n$75.52\n34%\n\n\nCentene Corp. CNC\n85%\n$64.37\n$85.47\n33%\n\n\nVertex Pharmaceuticals Inc. VRTX\n78%\n$198.05\n$262.14\n32%\n\n\nFedEx Corp. FDX\n78%\n$266.04\n$349.48\n31%\n\n\nDevon Energy Corp. DVN\n85%\n$29.17\n$38.19\n31%\n\n\nValero Energy Corp. VLO\n85%\n$64.70\n$84.06\n30%\n\n\nMastercard Inc. Class A MA\n84%\n$340.23\n$439.16\n29%\n\n\nZimmer Biomet Holdings Inc. ZBH\n79%\n$146.74\n$187.58\n28%\n\n\nSchlumberger Ltd. SLB\n79%\n$28.09\n$35.56\n27%\n\n\nT-Mobile US Inc. TMUS\n87%\n$136.00\n$172.00\n26%\n\n\nSource: FactSet\n\n\n\n\n\n\n\nClick on the tickers for more about each company.\nIf you see any stocks of interest, you should do your own research and form your own opinion about how likely a company is to remain competitive over the next decade. Tomi Kilgore has just written a detailed guide to the information available on MarketWatch's quote page. That's a great way to begin digging into any stock.","news_type":1},"isVote":1,"tweetType":1,"viewCount":620,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":883269386,"gmtCreate":1631244807245,"gmtModify":1676530507541,"author":{"id":"3556954148323654","authorId":"3556954148323654","name":"cart158","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3556954148323654","authorIdStr":"3556954148323654"},"themes":[],"htmlText":"Not worth","listText":"Not worth","text":"Not worth","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/883269386","repostId":"2166434154","repostType":4,"repost":{"id":"2166434154","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1631243007,"share":"https://ttm.financial/m/news/2166434154?lang=&edition=fundamental","pubTime":"2021-09-10 11:03","market":"us","language":"en","title":"Is GameStop Worth More Than $10 A Share? Analyst Slams 'Shameful' Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2166434154","media":"Benzinga","summary":"GameStop Corp (NYSE: GME) is trading lower after the company reported weak earnings results and failed to provide updates on its long-term transformation strategy.","content":"<p><b>GameStop Corp</b> (NYSE:GME) is trading lower&nbsp;after the company reported weak earnings results and failed to provide updates on its long-term transformation strategy.</p>\n<p>GameStop failed to provide color on its financial results or its long-term plan and even refrained from taking questions,&nbsp;Loop Capital's <b>Anthony Chukumba</b> said Thursday on CNBC's \"Squawk Box.\"</p>\n<p><b>What Happened:&nbsp;</b>GameStop reported a quarterly earnings loss of 76 cents per share, which came in below the estimate for a loss of 66 cents per share. The company reported quarterly revenue of $1.183 billion, which beat the estimate of $1.12 billion.</p>\n<p>The lack of clarity on the conference call was astounding, Chukumba said:&nbsp;\"It was&nbsp;shameful. It was disrespectful to their shareholders.\"</p>\n<p>He was&nbsp;skeptical&nbsp;of <b>Chewy Inc</b> (NYSE:CHWY) founder <b>Ryan Cohen's</b> ability to turn the company around.</p>\n<p>\"At some point we are going to have to come to the realization that the emperor has no clothes. There's no strategy and there's no turning this business around,\" Chukumba said.</p>\n<p>Co-host <b>Andrew Ross Sorkin</b>&nbsp;asked for his thoughts about the characterization&nbsp;of GameStop as a well-funded startup company.</p>\n<p>Startups grow sales at an extremely fast rate and although those companies usually lose money, it's easy to see when they may become profitable,&nbsp;Chukumba said, adding that in terms of GameStop, those characteristics are nowhere to be found.</p>\n<p>\"To liken this to an internet startup is an insult to internet startups,\" he said.</p>\n<p><b>Valuation:</b> The current valuation is nonsensical, Chukumba said.&nbsp;GameStop's market cap was just below $15 billion at publication time.</p>\n<p>Chukumba had a price target of $10 on the stock when he last covered it.</p>\n<p>\"I haven't covered the company for quite some time, but there's nothing to&nbsp;make me think that it's worth any more than [$10 per share]. For this stock to have a $15 billion valuation is the dumbest thing I've heard in quite some time,\" he said.</p>\n<p>Following his comments on the&nbsp;widely popular stock, Sorkin smiled and told Chukumba to \"stay safe.\"</p>\n<p><b>GME Price Action:</b> GameStop has traded&nbsp;as high as $483 and as low as $5.87 over a 52-week period.</p>\n<p>The stock rose 0.2% to $199.18&nbsp;on&nbsp;Thursday.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is GameStop Worth More Than $10 A Share? Analyst Slams 'Shameful' Earnings Call</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs GameStop Worth More Than $10 A Share? Analyst Slams 'Shameful' Earnings Call\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-09-10 11:03</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>GameStop Corp</b> (NYSE:GME) is trading lower&nbsp;after the company reported weak earnings results and failed to provide updates on its long-term transformation strategy.</p>\n<p>GameStop failed to provide color on its financial results or its long-term plan and even refrained from taking questions,&nbsp;Loop Capital's <b>Anthony Chukumba</b> said Thursday on CNBC's \"Squawk Box.\"</p>\n<p><b>What Happened:&nbsp;</b>GameStop reported a quarterly earnings loss of 76 cents per share, which came in below the estimate for a loss of 66 cents per share. The company reported quarterly revenue of $1.183 billion, which beat the estimate of $1.12 billion.</p>\n<p>The lack of clarity on the conference call was astounding, Chukumba said:&nbsp;\"It was&nbsp;shameful. It was disrespectful to their shareholders.\"</p>\n<p>He was&nbsp;skeptical&nbsp;of <b>Chewy Inc</b> (NYSE:CHWY) founder <b>Ryan Cohen's</b> ability to turn the company around.</p>\n<p>\"At some point we are going to have to come to the realization that the emperor has no clothes. There's no strategy and there's no turning this business around,\" Chukumba said.</p>\n<p>Co-host <b>Andrew Ross Sorkin</b>&nbsp;asked for his thoughts about the characterization&nbsp;of GameStop as a well-funded startup company.</p>\n<p>Startups grow sales at an extremely fast rate and although those companies usually lose money, it's easy to see when they may become profitable,&nbsp;Chukumba said, adding that in terms of GameStop, those characteristics are nowhere to be found.</p>\n<p>\"To liken this to an internet startup is an insult to internet startups,\" he said.</p>\n<p><b>Valuation:</b> The current valuation is nonsensical, Chukumba said.&nbsp;GameStop's market cap was just below $15 billion at publication time.</p>\n<p>Chukumba had a price target of $10 on the stock when he last covered it.</p>\n<p>\"I haven't covered the company for quite some time, but there's nothing to&nbsp;make me think that it's worth any more than [$10 per share]. For this stock to have a $15 billion valuation is the dumbest thing I've heard in quite some time,\" he said.</p>\n<p>Following his comments on the&nbsp;widely popular stock, Sorkin smiled and told Chukumba to \"stay safe.\"</p>\n<p><b>GME Price Action:</b> GameStop has traded&nbsp;as high as $483 and as low as $5.87 over a 52-week period.</p>\n<p>The stock rose 0.2% to $199.18&nbsp;on&nbsp;Thursday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CHWY":"Chewy, Inc.","GME":"游戏驿站"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166434154","content_text":"GameStop Corp (NYSE:GME) is trading lower after the company reported weak earnings results and failed to provide updates on its long-term transformation strategy.\nGameStop failed to provide color on its financial results or its long-term plan and even refrained from taking questions, Loop Capital's Anthony Chukumba said Thursday on CNBC's \"Squawk Box.\"\nWhat Happened: GameStop reported a quarterly earnings loss of 76 cents per share, which came in below the estimate for a loss of 66 cents per share. The company reported quarterly revenue of $1.183 billion, which beat the estimate of $1.12 billion.\nThe lack of clarity on the conference call was astounding, Chukumba said: \"It was shameful. It was disrespectful to their shareholders.\"\nHe was skeptical of Chewy Inc (NYSE:CHWY) founder Ryan Cohen's ability to turn the company around.\n\"At some point we are going to have to come to the realization that the emperor has no clothes. There's no strategy and there's no turning this business around,\" Chukumba said.\nCo-host Andrew Ross Sorkin asked for his thoughts about the characterization of GameStop as a well-funded startup company.\nStartups grow sales at an extremely fast rate and although those companies usually lose money, it's easy to see when they may become profitable, Chukumba said, adding that in terms of GameStop, those characteristics are nowhere to be found.\n\"To liken this to an internet startup is an insult to internet startups,\" he said.\nValuation: The current valuation is nonsensical, Chukumba said. GameStop's market cap was just below $15 billion at publication time.\nChukumba had a price target of $10 on the stock when he last covered it.\n\"I haven't covered the company for quite some time, but there's nothing to make me think that it's worth any more than [$10 per share]. For this stock to have a $15 billion valuation is the dumbest thing I've heard in quite some time,\" he said.\nFollowing his comments on the widely popular stock, Sorkin smiled and told Chukumba to \"stay safe.\"\nGME Price Action: GameStop has traded as high as $483 and as low as $5.87 over a 52-week period.\nThe stock rose 0.2% to $199.18 on Thursday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":403,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":886053880,"gmtCreate":1631540527340,"gmtModify":1676530570105,"author":{"id":"3556954148323654","authorId":"3556954148323654","name":"cart158","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3556954148323654","authorIdStr":"3556954148323654"},"themes":[],"htmlText":"Should buy this stock now?","listText":"Should buy this stock now?","text":"Should buy this stock now?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/886053880","repostId":"2167586988","repostType":4,"repost":{"id":"2167586988","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1631536350,"share":"https://ttm.financial/m/news/2167586988?lang=&edition=fundamental","pubTime":"2021-09-13 20:32","market":"us","language":"en","title":"Coinbase looking to raise $1.5 billion through debt offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2167586988","media":"Reuters","summary":"Sept 13 (Reuters) - Coinbase Global Inc is planning to raise about $1.5 billion through a debt offer","content":"<p>Sept 13 (Reuters) - Coinbase Global Inc&nbsp;is planning to raise about $1.5 billion through a debt offering to invest in product development and potential mergers and acquisitions, the U.S. cryptocurrency exchange said on Monday.</p>\n<p>The fundraising plans come less than a week after the company said U.S. regulators would sue the exchange if it went ahead with plans to launch a program allowing users to earn interest by lending digital assets.</p>\n<p>\"This capital raise represents an opportunity to bolster our already-strong balance sheet with low-cost capital,\" Coinbase said in a statement.</p>\n<p>As one of the largest cryptocurrency exchanges in the world, Coinbase has benefited from the growing adoption of digital assets, but has also taken a hit from the volatility and regulatory scrutiny around it.</p>\n<p>Since its debut in April, Coinbase shares have lost about 34% of their value.</p>\n<p>A month after listing, the company had said it would offer $1.25 billion in senior notes due 2026, to raise funds for general corporate purposes.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coinbase looking to raise $1.5 billion through debt offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoinbase looking to raise $1.5 billion through debt offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-09-13 20:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sept 13 (Reuters) - Coinbase Global Inc&nbsp;is planning to raise about $1.5 billion through a debt offering to invest in product development and potential mergers and acquisitions, the U.S. cryptocurrency exchange said on Monday.</p>\n<p>The fundraising plans come less than a week after the company said U.S. regulators would sue the exchange if it went ahead with plans to launch a program allowing users to earn interest by lending digital assets.</p>\n<p>\"This capital raise represents an opportunity to bolster our already-strong balance sheet with low-cost capital,\" Coinbase said in a statement.</p>\n<p>As one of the largest cryptocurrency exchanges in the world, Coinbase has benefited from the growing adoption of digital assets, but has also taken a hit from the volatility and regulatory scrutiny around it.</p>\n<p>Since its debut in April, Coinbase shares have lost about 34% of their value.</p>\n<p>A month after listing, the company had said it would offer $1.25 billion in senior notes due 2026, to raise funds for general corporate purposes.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COIN":"Coinbase Global, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167586988","content_text":"Sept 13 (Reuters) - Coinbase Global Inc is planning to raise about $1.5 billion through a debt offering to invest in product development and potential mergers and acquisitions, the U.S. cryptocurrency exchange said on Monday.\nThe fundraising plans come less than a week after the company said U.S. regulators would sue the exchange if it went ahead with plans to launch a program allowing users to earn interest by lending digital assets.\n\"This capital raise represents an opportunity to bolster our already-strong balance sheet with low-cost capital,\" Coinbase said in a statement.\nAs one of the largest cryptocurrency exchanges in the world, Coinbase has benefited from the growing adoption of digital assets, but has also taken a hit from the volatility and regulatory scrutiny around it.\nSince its debut in April, Coinbase shares have lost about 34% of their value.\nA month after listing, the company had said it would offer $1.25 billion in senior notes due 2026, to raise funds for general corporate purposes.","news_type":1},"isVote":1,"tweetType":1,"viewCount":371,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":883269260,"gmtCreate":1631244840250,"gmtModify":1676530507565,"author":{"id":"3556954148323654","authorId":"3556954148323654","name":"cart158","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3556954148323654","authorIdStr":"3556954148323654"},"themes":[],"htmlText":"Time to buy?","listText":"Time to buy?","text":"Time to buy?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883269260","repostId":"2166495033","repostType":4,"repost":{"id":"2166495033","pubTimestamp":1631244694,"share":"https://ttm.financial/m/news/2166495033?lang=&edition=fundamental","pubTime":"2021-09-10 11:31","market":"us","language":"en","title":"These 3 EV Stocks Are Down More Than 40% This Year. Time to Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2166495033","media":"Motley Fool","summary":"One of the stocks has fallen 69% so far in this year.","content":"<p>The electric vehicle sector is rapidly evolving. At the same time, the players in the segment are facing increasing competition both from newer entrants as well as legacy automakers who are leaving no stone unturned to retain their shares of this growing market. As things stand today, it's a difficult task to predict who will survive in the EV race.</p>\n<p>Let's look at three EV stocks --<b> Workhorse Group </b>(NASDAQ:WKHS), <b>Lordstown Motors</b> (NASDAQ:RIDE), and <b>Canoo</b> (NASDAQ:GOEV) -- that have each fallen more than 40% in 2021 and see whether they are attractive buys right now.</p>\n<h2>Why are EV stocks down?</h2>\n<p>EV stocks have seen a lot of investor interest in recent years. The growth of <b>Tesla</b> and its stock largely fueled investors' enthusiasm for EV stocks. President Biden's announcement of an intention to replace federal government's huge vehicle fleet with EVs added to this euphoria.</p>\n<p>The narrative has, however, shifted a bit in recent months. The possibility of production delays due to a semiconductor shortage and the spread of the delta variant, concerns relating to overvaluation of EV stocks, and accidents involving self-driving features have resulted in a sell-off in EV stocks.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3ccaffd1e3a9b8aafa29951d15c7dd30\" tg-width=\"720\" tg-height=\"387\" width=\"100%\" height=\"auto\"><span>WKHS data by YCharts</span></p>\n<p>Despite the latest fall, most EV stocks are trading at levels higher than they were trading at months ago. As an example, Workhorse Group stock is down more than 50% since the start of 2021. Moreover, it is 78% off its all-time high level of a little over $41, which the stock reached February. While the current price looks like a bargain opportunity, it doesn't if we go a little bit back in the stock's price history. Even after the recent fall, Workhorse stock is still trading at a price 140% higher than two years ago.</p>\n<h2>Workhorse Group</h2>\n<p>Like other EV names, Workhorse Group's stock rose drastically in the second half of last year up to February this year. The stock's spectacular rise was driven by the company's first deliveries, the possibility of a huge order from the U.S. Postal Service, and overall enthusiasm for EV stocks.</p>\n<p>However, Workhorse Group is facing a string of issues, starting with not winning&nbsp;the Postal Service order. Moreover, the company has significantly fallen behind on its production plans. In July 2020, Workhorse delivered only two electric vans. The number of deliveries increased to just 14 in the second quarter this year. The company has consistently failed to deliver based on its guidance. For example, management projected it would produce 300 to 400 vehicles by the end of 2020. It has delivered total 20 vehicles so far in 2021.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F642114%2Fwoman-charging-electric-car-while-using-smartphone.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"451\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<p>Workhorse has recently replaced its CEO, is revising the design of its very first model, and is reportedly facing an investigation from the Securities and Exchange Commission. Finally, Workhorse is competing in an EV segment that established players already have their sights on.</p>\n<h2>Lordstown Motors</h2>\n<p>Like Workhorse, the list of issues facing pre-revenue company Lordstown Motors is long. From being a short-seller's target, to a going concern warning (a going concern is issued when a company has doubts about its ability to continue operating for at least a year),&nbsp;to leadership departure, to fierce competition, Lordstown has had numerous problems to deal with. The company expects to begin deliveries in the second quarter of next year.</p>\n<p>Lordstown has appointed Daniel A. Ninivaggi, with extensive experience in auto and transport industries, as its new CEO. However, it might be too early to say if the leadership change can take Lordstown out of its troubles.</p>\n<h2>Canoo</h2>\n<p>Listing in December last year, Canoo is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the newest EV kids on the block. To bring its products to market quickly, as well as to expand its geographic footprint, Canoo has partnered with VDL Nedcar, a contract vehicle manufacturer in the Netherlands. Canoo expects to deliver between 500 and 1,000 vehicles in 2022 and 15,000 vehicles in 2023 under this agreement. At the same time, the company is manufacturing its own plant in Oklahoma.</p>\n<p>Canoo's co-founder and former CEO Ulrich Kranz resigned hastily in April, and its executive chairman Tony Aquila is the company's new CEO. The new leadership has announced certain key changes in the company's growth focus, especially relating to its contract engineering plans and subscription service model. With the first vehicles still several months away, there are significant risks involved here.</p>\n<h2>There are reasons behind the steep fall</h2>\n<p>While Lordstown and Canoo are facing challenges even before their first deliveries, Workhorse Group is facing issues with its first models, and is redesigning them. Workhorse is also significantly behind in its production plans.</p>\n<p>The EV segment has become increasingly competitive with pure-play EV companies like Tesla as well as legacy automakers launching electric versions of several of their models. The challenges ahead for EV start-ups like Workhorse Group, Lordstown, and Canoo are tall. Additionally, Lordstown and Canoo are right now struggling to start production while Workhorse is finding it difficult to ramp up, even as its first model is seemingly encountering technical difficulties.</p>\n<p>All in all, there are reasons why the three stocks are down. The best course is to avoid these stocks and instead go for more credible EV stories.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These 3 EV Stocks Are Down More Than 40% This Year. Time to Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese 3 EV Stocks Are Down More Than 40% This Year. Time to Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-10 11:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/these-3-ev-stocks-are-down-more-than-40-this-year/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The electric vehicle sector is rapidly evolving. At the same time, the players in the segment are facing increasing competition both from newer entrants as well as legacy automakers who are leaving no...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/these-3-ev-stocks-are-down-more-than-40-this-year/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GOEV":"Canoo Inc.","WKHS":"Workhorse Group, Inc."},"source_url":"https://www.fool.com/investing/2021/09/09/these-3-ev-stocks-are-down-more-than-40-this-year/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166495033","content_text":"The electric vehicle sector is rapidly evolving. At the same time, the players in the segment are facing increasing competition both from newer entrants as well as legacy automakers who are leaving no stone unturned to retain their shares of this growing market. As things stand today, it's a difficult task to predict who will survive in the EV race.\nLet's look at three EV stocks -- Workhorse Group (NASDAQ:WKHS), Lordstown Motors (NASDAQ:RIDE), and Canoo (NASDAQ:GOEV) -- that have each fallen more than 40% in 2021 and see whether they are attractive buys right now.\nWhy are EV stocks down?\nEV stocks have seen a lot of investor interest in recent years. The growth of Tesla and its stock largely fueled investors' enthusiasm for EV stocks. President Biden's announcement of an intention to replace federal government's huge vehicle fleet with EVs added to this euphoria.\nThe narrative has, however, shifted a bit in recent months. The possibility of production delays due to a semiconductor shortage and the spread of the delta variant, concerns relating to overvaluation of EV stocks, and accidents involving self-driving features have resulted in a sell-off in EV stocks.\nWKHS data by YCharts\nDespite the latest fall, most EV stocks are trading at levels higher than they were trading at months ago. As an example, Workhorse Group stock is down more than 50% since the start of 2021. Moreover, it is 78% off its all-time high level of a little over $41, which the stock reached February. While the current price looks like a bargain opportunity, it doesn't if we go a little bit back in the stock's price history. Even after the recent fall, Workhorse stock is still trading at a price 140% higher than two years ago.\nWorkhorse Group\nLike other EV names, Workhorse Group's stock rose drastically in the second half of last year up to February this year. The stock's spectacular rise was driven by the company's first deliveries, the possibility of a huge order from the U.S. Postal Service, and overall enthusiasm for EV stocks.\nHowever, Workhorse Group is facing a string of issues, starting with not winning the Postal Service order. Moreover, the company has significantly fallen behind on its production plans. In July 2020, Workhorse delivered only two electric vans. The number of deliveries increased to just 14 in the second quarter this year. The company has consistently failed to deliver based on its guidance. For example, management projected it would produce 300 to 400 vehicles by the end of 2020. It has delivered total 20 vehicles so far in 2021.\nImage source: Getty Images.\nWorkhorse has recently replaced its CEO, is revising the design of its very first model, and is reportedly facing an investigation from the Securities and Exchange Commission. Finally, Workhorse is competing in an EV segment that established players already have their sights on.\nLordstown Motors\nLike Workhorse, the list of issues facing pre-revenue company Lordstown Motors is long. From being a short-seller's target, to a going concern warning (a going concern is issued when a company has doubts about its ability to continue operating for at least a year), to leadership departure, to fierce competition, Lordstown has had numerous problems to deal with. The company expects to begin deliveries in the second quarter of next year.\nLordstown has appointed Daniel A. Ninivaggi, with extensive experience in auto and transport industries, as its new CEO. However, it might be too early to say if the leadership change can take Lordstown out of its troubles.\nCanoo\nListing in December last year, Canoo is one of the newest EV kids on the block. To bring its products to market quickly, as well as to expand its geographic footprint, Canoo has partnered with VDL Nedcar, a contract vehicle manufacturer in the Netherlands. Canoo expects to deliver between 500 and 1,000 vehicles in 2022 and 15,000 vehicles in 2023 under this agreement. At the same time, the company is manufacturing its own plant in Oklahoma.\nCanoo's co-founder and former CEO Ulrich Kranz resigned hastily in April, and its executive chairman Tony Aquila is the company's new CEO. The new leadership has announced certain key changes in the company's growth focus, especially relating to its contract engineering plans and subscription service model. With the first vehicles still several months away, there are significant risks involved here.\nThere are reasons behind the steep fall\nWhile Lordstown and Canoo are facing challenges even before their first deliveries, Workhorse Group is facing issues with its first models, and is redesigning them. Workhorse is also significantly behind in its production plans.\nThe EV segment has become increasingly competitive with pure-play EV companies like Tesla as well as legacy automakers launching electric versions of several of their models. The challenges ahead for EV start-ups like Workhorse Group, Lordstown, and Canoo are tall. Additionally, Lordstown and Canoo are right now struggling to start production while Workhorse is finding it difficult to ramp up, even as its first model is seemingly encountering technical difficulties.\nAll in all, there are reasons why the three stocks are down. The best course is to avoid these stocks and instead go for more credible EV stories.","news_type":1},"isVote":1,"tweetType":1,"viewCount":331,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":883269644,"gmtCreate":1631244823288,"gmtModify":1676530507549,"author":{"id":"3556954148323654","authorId":"3556954148323654","name":"cart158","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3556954148323654","authorIdStr":"3556954148323654"},"themes":[],"htmlText":"How how xia","listText":"How how xia","text":"How how xia","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883269644","repostId":"2166674328","repostType":4,"isVote":1,"tweetType":1,"viewCount":351,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":894757421,"gmtCreate":1628859967563,"gmtModify":1676529877277,"author":{"id":"3556954148323654","authorId":"3556954148323654","name":"cart158","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3556954148323654","authorIdStr":"3556954148323654"},"themes":[],"htmlText":"I want to invest also","listText":"I want to invest also","text":"I want to invest also","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/894757421","repostId":"1118408635","repostType":4,"repost":{"id":"1118408635","pubTimestamp":1628855083,"share":"https://ttm.financial/m/news/1118408635?lang=&edition=fundamental","pubTime":"2021-08-13 19:44","market":"uk","language":"en","title":"Europe Stocks Near Longest Win Streak Since 1999: Markets Wrap","url":"https://stock-news.laohu8.com/highlight/detail?id=1118408635","media":"Bloomberg","summary":"(Bloomberg) -- European stocks headed for the longest winning streak since 1999 as bullishness swept","content":"<p>(Bloomberg) -- European stocks headed for the longest winning streak since 1999 as bullishness swept across markets after a blowout earnings season and economic recovery out of lockdowns.</p>\n<p>The Stoxx 600 Index rose 0.2%, poised for a tenth straight record close, and France’s CAC 40 approached the highest in more than two decades. U.S. stock futures were steady after the S&amp;P 500 closed at a record high. Walt Disney Co. advanced in pre-market trading after reporting better-than-expected quarterly results.</p>\n<p>Europe and the U.S. have pushed ahead with inoculations, attracting investors as travel and reopenings gather pace. Traders plowed $1.5 billion into European equity funds this week, the most in two months, according to Bank of America. Along with the wave of strong corporate results, the global backdrop is sufficient for some strategists to predict a rebound in the reflation trade tied to economic revival.</p>\n<p>“It’s really hard to keep people back, or put people back, in lockdown,” Ann Miletti, head of active equity at Wells Fargo Asset Management, said in an interview on Bloomberg Television. She flagged “pent-up demand” but also warned of the risk of an equity correction after a prolonged period of calm.</p>\n<p>The CAC 40’s 24% rise so far this year ranks second only to some Nordic benchmarks among major western European equity indexes. Stuffed with cyclical shares, the gauge may be headed for further outperformance on signs the global economy is shrugging off the delta variant.</p>\n<p>Elsewhere, Treasury yields dipped alongside the dollar. Bitcoin traded around $46,000.</p>\n<p>For more market analysis read our MLIV blog.</p>\n<p>These are the main moves in markets:</p>\n<p>Stocks</p>\n<p>Futures on the S&amp;P 500 were little changed as of 6:38 a.m. New York timeFutures on the Nasdaq 100 were little changedFutures on the Dow Jones Industrial Average rose 0.1%The Stoxx Europe 600 rose 0.2%The MSCI World index rose 0.1%</p>\n<p>Currencies</p>\n<p>The Bloomberg Dollar Spot Index was little changedThe euro rose 0.2% to $1.1749The British pound was little changed at $1.3797The Japanese yen rose 0.1% to 110.27 per dollar</p>\n<p>Bonds</p>\n<p>The yield on 10-year Treasuries declined two basis points to 1.34%Germany’s 10-year yield was little changed at -0.46%Britain’s 10-year yield declined one basis point to 0.59%</p>\n<p>Commodities</p>\n<p>West Texas Intermediate crude fell 0.4% to $68.81 a barrelGold futures rose 0.6% to $1,761.70 an ounce.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Europe Stocks Near Longest Win Streak Since 1999: Markets Wrap</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEurope Stocks Near Longest Win Streak Since 1999: Markets Wrap\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-13 19:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/asia-stocks-set-cautious-start-221627941.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- European stocks headed for the longest winning streak since 1999 as bullishness swept across markets after a blowout earnings season and economic recovery out of lockdowns.\nThe Stoxx ...</p>\n\n<a href=\"https://finance.yahoo.com/news/asia-stocks-set-cautious-start-221627941.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".UKX.UK":"富时100指数"},"source_url":"https://finance.yahoo.com/news/asia-stocks-set-cautious-start-221627941.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118408635","content_text":"(Bloomberg) -- European stocks headed for the longest winning streak since 1999 as bullishness swept across markets after a blowout earnings season and economic recovery out of lockdowns.\nThe Stoxx 600 Index rose 0.2%, poised for a tenth straight record close, and France’s CAC 40 approached the highest in more than two decades. U.S. stock futures were steady after the S&P 500 closed at a record high. Walt Disney Co. advanced in pre-market trading after reporting better-than-expected quarterly results.\nEurope and the U.S. have pushed ahead with inoculations, attracting investors as travel and reopenings gather pace. Traders plowed $1.5 billion into European equity funds this week, the most in two months, according to Bank of America. Along with the wave of strong corporate results, the global backdrop is sufficient for some strategists to predict a rebound in the reflation trade tied to economic revival.\n“It’s really hard to keep people back, or put people back, in lockdown,” Ann Miletti, head of active equity at Wells Fargo Asset Management, said in an interview on Bloomberg Television. She flagged “pent-up demand” but also warned of the risk of an equity correction after a prolonged period of calm.\nThe CAC 40’s 24% rise so far this year ranks second only to some Nordic benchmarks among major western European equity indexes. Stuffed with cyclical shares, the gauge may be headed for further outperformance on signs the global economy is shrugging off the delta variant.\nElsewhere, Treasury yields dipped alongside the dollar. Bitcoin traded around $46,000.\nFor more market analysis read our MLIV blog.\nThese are the main moves in markets:\nStocks\nFutures on the S&P 500 were little changed as of 6:38 a.m. New York timeFutures on the Nasdaq 100 were little changedFutures on the Dow Jones Industrial Average rose 0.1%The Stoxx Europe 600 rose 0.2%The MSCI World index rose 0.1%\nCurrencies\nThe Bloomberg Dollar Spot Index was little changedThe euro rose 0.2% to $1.1749The British pound was little changed at $1.3797The Japanese yen rose 0.1% to 110.27 per dollar\nBonds\nThe yield on 10-year Treasuries declined two basis points to 1.34%Germany’s 10-year yield was little changed at -0.46%Britain’s 10-year yield declined one basis point to 0.59%\nCommodities\nWest Texas Intermediate crude fell 0.4% to $68.81 a barrelGold futures rose 0.6% to $1,761.70 an ounce.","news_type":1},"isVote":1,"tweetType":1,"viewCount":188,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":898252212,"gmtCreate":1628504123536,"gmtModify":1703507191536,"author":{"id":"3556954148323654","authorId":"3556954148323654","name":"cart158","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3556954148323654","authorIdStr":"3556954148323654"},"themes":[],"htmlText":"Think stock will go up?","listText":"Think stock will go up?","text":"Think stock will go up?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/898252212","repostId":"2158284412","repostType":2,"repost":{"id":"2158284412","pubTimestamp":1628493368,"share":"https://ttm.financial/m/news/2158284412?lang=&edition=fundamental","pubTime":"2021-08-09 15:16","market":"hk","language":"zh","title":"财报前瞻 | 疫情冲击下高估值能否维系?爱彼迎(ABNB.US)业绩指引至关重要","url":"https://stock-news.laohu8.com/highlight/detail?id=2158284412","media":"智通财经","summary":"智通财经APP获悉，爱彼迎将于美东时间8月12日盘后公布第二季度财报。华尔街普遍预计爱彼迎每股亏损0.48美元，营收为12.3亿美元;据悉，该公司去年同期每股亏损1.95美元，营收8.8694亿美元。目前市场普遍的疑问是：爱彼迎还能维持目前的高估值吗?爱彼迎股价在过去六个月下跌了约23%，而标普500指数上涨了14%，这表明市场正在重新衡量该股票的价值。","content":"<html><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/ABNB\">爱彼迎</a>(ABNB.US)将于美东时间8月12日盘后(北京时间8月13日早间)公布第二季度财报。华尔街普遍预计爱彼迎每股亏损0.48美元，营收为12.3亿美元;据悉，该公司去年同期每股亏损1.95美元，营收8.8694亿美元。</p><p>目前市场普遍的疑问是：爱彼迎还能维持目前的高估值吗?虽然该公司是住房共享市场的领导者，但德尔塔变异病毒在全球范围内的爆发可能会打乱该公司的发展规划。爱彼迎股价在过去六个月下跌了约23%，而标普500指数上涨了14%，这表明市场正在重新衡量该股票的价值。另一方面，该股的表现超过了<a href=\"https://laohu8.com/S/EXPE\">Expedia</a>(EXPE.US)和<a href=\"https://laohu8.com/S/TRIP\">猫途鹰</a>(TRIP.US)等同类企业的股票。</p><p>不可否认的是，爱彼迎拥有吸引投资者的商业模式和竞争优势，分析师们普遍认为其远胜于竞争对手，这也促使BTIG分析师Jake \nFuller最近将该股评级从“中性”上调至“买入”。Fuller表示，如果封锁措施变得严格起来，该公司有能力更好地抵御疫情带来的不确定性。该分析师将Airbnb的目标价定在170美元，略高于168美元的华尔街平均目标价。</p><p>尽管该股估值过高，但Fuller表示，爱彼迎作为全球最优秀的数字化住宿服务公司，这一龙头地位能够支撑起它的高估值，如果说要证实这一点，美东时间周四的Q2业绩和本年度业绩指引，尤其是后者，将尤为关键。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>财报前瞻 | 疫情冲击下高估值能否维系?爱彼迎(ABNB.US)业绩指引至关重要</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n财报前瞻 | 疫情冲击下高估值能否维系?爱彼迎(ABNB.US)业绩指引至关重要\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-09 15:16 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/529610.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，爱彼迎(ABNB.US)将于美东时间8月12日盘后(北京时间8月13日早间)公布第二季度财报。华尔街普遍预计爱彼迎每股亏损0.48美元，营收为12.3亿美元;据悉，该公司去年同期每股亏损1.95美元，营收8.8694亿美元。目前市场普遍的疑问是：爱彼迎还能维持目前的高估值吗?虽然该公司是住房共享市场的领导者，但德尔塔变异病毒在全球范围内的爆发可能会打乱该公司的发展规划。爱彼迎...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/529610.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750","relate_stocks":{"ABNB":"爱彼迎"},"source_url":"http://www.zhitongcaijing.com/content/detail/529610.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158284412","content_text":"智通财经APP获悉，爱彼迎(ABNB.US)将于美东时间8月12日盘后(北京时间8月13日早间)公布第二季度财报。华尔街普遍预计爱彼迎每股亏损0.48美元，营收为12.3亿美元;据悉，该公司去年同期每股亏损1.95美元，营收8.8694亿美元。目前市场普遍的疑问是：爱彼迎还能维持目前的高估值吗?虽然该公司是住房共享市场的领导者，但德尔塔变异病毒在全球范围内的爆发可能会打乱该公司的发展规划。爱彼迎股价在过去六个月下跌了约23%，而标普500指数上涨了14%，这表明市场正在重新衡量该股票的价值。另一方面，该股的表现超过了Expedia(EXPE.US)和猫途鹰(TRIP.US)等同类企业的股票。不可否认的是，爱彼迎拥有吸引投资者的商业模式和竞争优势，分析师们普遍认为其远胜于竞争对手，这也促使BTIG分析师Jake \nFuller最近将该股评级从“中性”上调至“买入”。Fuller表示，如果封锁措施变得严格起来，该公司有能力更好地抵御疫情带来的不确定性。该分析师将Airbnb的目标价定在170美元，略高于168美元的华尔街平均目标价。尽管该股估值过高，但Fuller表示，爱彼迎作为全球最优秀的数字化住宿服务公司，这一龙头地位能够支撑起它的高估值，如果说要证实这一点，美东时间周四的Q2业绩和本年度业绩指引，尤其是后者，将尤为关键。","news_type":1},"isVote":1,"tweetType":1,"viewCount":183,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":804769431,"gmtCreate":1627981064623,"gmtModify":1703499032102,"author":{"id":"3556954148323654","authorId":"3556954148323654","name":"cart158","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3556954148323654","authorIdStr":"3556954148323654"},"themes":[],"htmlText":"Hope time to buy the stock come","listText":"Hope time to buy the stock come","text":"Hope time to buy the stock come","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/804769431","repostId":"1104668581","repostType":4,"repost":{"id":"1104668581","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1627977934,"share":"https://ttm.financial/m/news/1104668581?lang=&edition=fundamental","pubTime":"2021-08-03 16:05","market":"us","language":"en","title":"Apple Will Have To Face Patent Infringement Lawsuit Over Apple Watch Heart Rate Sensor, Rules Court","url":"https://stock-news.laohu8.com/highlight/detail?id=1104668581","media":"Benzinga","summary":"Apple Inc. will have to face a patent infringement lawsuit over the heart rate sensor technology in ","content":"<p><b><a href=\"https://laohu8.com/S/AAPL\">Apple</a> Inc.</b>&nbsp;will have to face a patent infringement lawsuit over the heart rate sensor technology in the <a href=\"https://laohu8.com/S/AAPL\">Apple</a> Watch, AppleInsiderreportedMonday, citing a ruling by the U.S. Court of Appeals for the Federal Circuit.</p>\n<p><b>What Happened</b>: The original lawsuit - filed by&nbsp;<b>Omni MedSci Inc.</b>&nbsp;in 2018 - had alleged that Apple Watch’s heart rate measurement technology infringed on multiple patents owned by the company, as per the report.</p>\n<p>Apple’s move to get the lawsuit dismissed was denied by a U.S. District Court. The case was brought to the Federal Circuit after the<b>Tim Cook</b>-led company appealed the decision, the report noted.</p>\n<p>The patents were reportedly owned by University of Michigan professor&nbsp;<b>Mohammed Islam</b>, who later assigned the patent rights to Omni MedSci.</p>\n<p>However, Apple had argued that the patents actually belonged to the University of Michigan, citing Islam’s employment agreement with the university, as per the report. The federal circuit disagreed with the tech giant’s argument.</p>\n<p><b>Why It Matters:</b>&nbsp;Apple is facing other lawsuits too related to the Apple Watch.It wasreportedin May that privately-held medical device maker<b>AliveCor Inc.</b>filed a federal antitrust lawsuit against the Cupertino-based company, accusing it of monopolizing the market for heart-rate technology for the Apple Watch.</p>\n<p>The Apple Watch is an important product for Apple and is part of the company’s wearables, home, and accessories segment that generated sales of $8.78 billion in the recent third quarter, up 36% year-over-year.</p>\n<p><b>Price Action</b>: Apple shares closed 0.2% lower in Monday’s trading session at $145.52.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title> Apple Will Have To Face Patent Infringement Lawsuit Over Apple Watch Heart Rate Sensor, Rules Court</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n Apple Will Have To Face Patent Infringement Lawsuit Over Apple Watch Heart Rate Sensor, Rules Court\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-03 16:05</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b><a href=\"https://laohu8.com/S/AAPL\">Apple</a> Inc.</b>&nbsp;will have to face a patent infringement lawsuit over the heart rate sensor technology in the <a href=\"https://laohu8.com/S/AAPL\">Apple</a> Watch, AppleInsiderreportedMonday, citing a ruling by the U.S. Court of Appeals for the Federal Circuit.</p>\n<p><b>What Happened</b>: The original lawsuit - filed by&nbsp;<b>Omni MedSci Inc.</b>&nbsp;in 2018 - had alleged that Apple Watch’s heart rate measurement technology infringed on multiple patents owned by the company, as per the report.</p>\n<p>Apple’s move to get the lawsuit dismissed was denied by a U.S. District Court. The case was brought to the Federal Circuit after the<b>Tim Cook</b>-led company appealed the decision, the report noted.</p>\n<p>The patents were reportedly owned by University of Michigan professor&nbsp;<b>Mohammed Islam</b>, who later assigned the patent rights to Omni MedSci.</p>\n<p>However, Apple had argued that the patents actually belonged to the University of Michigan, citing Islam’s employment agreement with the university, as per the report. The federal circuit disagreed with the tech giant’s argument.</p>\n<p><b>Why It Matters:</b>&nbsp;Apple is facing other lawsuits too related to the Apple Watch.It wasreportedin May that privately-held medical device maker<b>AliveCor Inc.</b>filed a federal antitrust lawsuit against the Cupertino-based company, accusing it of monopolizing the market for heart-rate technology for the Apple Watch.</p>\n<p>The Apple Watch is an important product for Apple and is part of the company’s wearables, home, and accessories segment that generated sales of $8.78 billion in the recent third quarter, up 36% year-over-year.</p>\n<p><b>Price Action</b>: Apple shares closed 0.2% lower in Monday’s trading session at $145.52.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"03086":"华夏纳指","09086":"华夏纳指-U","AAPL":"苹果"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104668581","content_text":"Apple Inc. will have to face a patent infringement lawsuit over the heart rate sensor technology in the Apple Watch, AppleInsiderreportedMonday, citing a ruling by the U.S. Court of Appeals for the Federal Circuit.\nWhat Happened: The original lawsuit - filed by Omni MedSci Inc. in 2018 - had alleged that Apple Watch’s heart rate measurement technology infringed on multiple patents owned by the company, as per the report.\nApple’s move to get the lawsuit dismissed was denied by a U.S. District Court. The case was brought to the Federal Circuit after theTim Cook-led company appealed the decision, the report noted.\nThe patents were reportedly owned by University of Michigan professor Mohammed Islam, who later assigned the patent rights to Omni MedSci.\nHowever, Apple had argued that the patents actually belonged to the University of Michigan, citing Islam’s employment agreement with the university, as per the report. The federal circuit disagreed with the tech giant’s argument.\nWhy It Matters: Apple is facing other lawsuits too related to the Apple Watch.It wasreportedin May that privately-held medical device makerAliveCor Inc.filed a federal antitrust lawsuit against the Cupertino-based company, accusing it of monopolizing the market for heart-rate technology for the Apple Watch.\nThe Apple Watch is an important product for Apple and is part of the company’s wearables, home, and accessories segment that generated sales of $8.78 billion in the recent third quarter, up 36% year-over-year.\nPrice Action: Apple shares closed 0.2% lower in Monday’s trading session at $145.52.","news_type":1},"isVote":1,"tweetType":1,"viewCount":153,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":886164377,"gmtCreate":1631576203999,"gmtModify":1676530577527,"author":{"id":"3556954148323654","authorId":"3556954148323654","name":"cart158","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3556954148323654","authorIdStr":"3556954148323654"},"themes":[],"htmlText":"I like abnb","listText":"I like abnb","text":"I like abnb","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/886164377","repostId":"1144988530","repostType":4,"repost":{"id":"1144988530","pubTimestamp":1631545689,"share":"https://ttm.financial/m/news/1144988530?lang=&edition=fundamental","pubTime":"2021-09-13 23:08","market":"us","language":"en","title":"Twitter, Airbnb, and Other Internet Stocks Just Got New Ratings. Here Are the Highlights.","url":"https://stock-news.laohu8.com/highlight/detail?id=1144988530","media":"Barrons","summary":"Investors in the internet sector are abuzz Monday after a Goldman Sachs analyst picked up coverage o","content":"<p>Investors in the internet sector are abuzz Monday after a Goldman Sachs analyst picked up coverage of the group, offering new ratings on 17 of the largest stocks. His calls made waves with the stocks to start the week.</p>\n<p>Analyst Eric Sheridan’s views on the stocks shouldn’t come as a total surprise to institutional investors; He joined Goldman in July after a nearly nine-year run as an analyst on the group at UBS. Sheridan is generally bullish on the sector, seeing opportunities for investors to “capture a mixture” of growth,</p>\n<p></p>\n<p>increasing free cash flow, and capital return to shareholders.</p>\n<p>“In our view, the industry still has ample opportunities for secular revenue growth and increased operating efficiencies on the back of building scale in the coming years,” he wrote in the 226-page report. “That being said, we are not uniformly bullish given the fact that many companies either have forward growth more than priced into their equity at current levels.”</p>\n<p>Sheridan set Buy ratings on&nbsp;Amazon.&nbsp;com (ticker: AMZN),Facebook&nbsp;(FB),Alphabet&nbsp;(GOOGL),Snap&nbsp;(SNAP), Uber Technologies&nbsp;(UBER),Lyft (LYFT), and Expedia&nbsp;(EXPE).</p>\n<p>“Our Buy ratings are reflective of companies where the market is still under-appreciating the prospects for long-term compounded growth and/or longer-term operating margin structures as reflected in current valuation,” Sheridan said. “In addition, our operating estimates broadly sit above consensus estimates for these companies over the next 12-24 months.”</p>\n<p>He put Neutral ratings on&nbsp;Pinterest&nbsp;(PINS),Chewy&nbsp;(CHWY),Netflix&nbsp;(NFLX),Spotify Technology&nbsp;(SPOT),Peloton Interactive&nbsp;(PTON),Booking Holdings&nbsp;(BKNG), and&nbsp;DoorDash&nbsp;(DASH).</p>\n<p>He gave Sell ratings on both&nbsp;Airbnb&nbsp;(ABNB) and&nbsp;Twitter&nbsp;(TWTR).</p>\n<p>All nine of the stocks Sheridan started with Neutral or Sell ratings were losing ground Monday, with the largest losses hitting Twitter and Airbnb. Both Chewy and Spotify were down more than 2%.</p>\n<p>On Twitter, Sheridan set a target price of $60, about 8% below recent levels. He noted that his five-year financial forecasts on the company are “broadly below current consensus estimates.” He thinks the company will fall short of Twitter’s own user and revenue goals laid out at its February 2021 analyst day.</p>\n<p>On Airbnb, Sheridan’s price target is $132, which implies about a 20% drop from recent levels. Sheridan said the company is “a strong player with runway for growth and margin expansion,” but he also expects “a volatile travel environment ahead,” finds the online travel market to be “relatively mature,” and sees “high levels of competitive intensity.” He added that his forward estimates are well below Street estimates.</p>\n<p>As part of the note, Sheridan laid out a list of 10 themes he sees for the internet group: blurring lines between e-commerce and advertising; the rise of the creator economy; streaming media reaching global scale, but with content cost questions; the shift of local commerce online; the growth of subscription-based services, but with potential consumer fatigue; the growth of cloud computing; the emergence of augmented reality and the metaverse; more personalized online travel services; growing costs from regulation; and the rise of the decentralized web.</p>\n<p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Twitter, Airbnb, and Other Internet Stocks Just Got New Ratings. Here Are the Highlights. </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTwitter, Airbnb, and Other Internet Stocks Just Got New Ratings. Here Are the Highlights. \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-13 23:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/twitter-airbnb-major-internet-stocks-51631545160?mod=hp_LATEST><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors in the internet sector are abuzz Monday after a Goldman Sachs analyst picked up coverage of the group, offering new ratings on 17 of the largest stocks. His calls made waves with the stocks ...</p>\n\n<a href=\"https://www.barrons.com/articles/twitter-airbnb-major-internet-stocks-51631545160?mod=hp_LATEST\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","ABNB":"爱彼迎","SNAP":"Snap Inc","UBER":"优步","TWTR":"Twitter"},"source_url":"https://www.barrons.com/articles/twitter-airbnb-major-internet-stocks-51631545160?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144988530","content_text":"Investors in the internet sector are abuzz Monday after a Goldman Sachs analyst picked up coverage of the group, offering new ratings on 17 of the largest stocks. His calls made waves with the stocks to start the week.\nAnalyst Eric Sheridan’s views on the stocks shouldn’t come as a total surprise to institutional investors; He joined Goldman in July after a nearly nine-year run as an analyst on the group at UBS. Sheridan is generally bullish on the sector, seeing opportunities for investors to “capture a mixture” of growth,\n\nincreasing free cash flow, and capital return to shareholders.\n“In our view, the industry still has ample opportunities for secular revenue growth and increased operating efficiencies on the back of building scale in the coming years,” he wrote in the 226-page report. “That being said, we are not uniformly bullish given the fact that many companies either have forward growth more than priced into their equity at current levels.”\nSheridan set Buy ratings on Amazon. com (ticker: AMZN),Facebook (FB),Alphabet (GOOGL),Snap (SNAP), Uber Technologies (UBER),Lyft (LYFT), and Expedia (EXPE).\n“Our Buy ratings are reflective of companies where the market is still under-appreciating the prospects for long-term compounded growth and/or longer-term operating margin structures as reflected in current valuation,” Sheridan said. “In addition, our operating estimates broadly sit above consensus estimates for these companies over the next 12-24 months.”\nHe put Neutral ratings on Pinterest (PINS),Chewy (CHWY),Netflix (NFLX),Spotify Technology (SPOT),Peloton Interactive (PTON),Booking Holdings (BKNG), and DoorDash (DASH).\nHe gave Sell ratings on both Airbnb (ABNB) and Twitter (TWTR).\nAll nine of the stocks Sheridan started with Neutral or Sell ratings were losing ground Monday, with the largest losses hitting Twitter and Airbnb. Both Chewy and Spotify were down more than 2%.\nOn Twitter, Sheridan set a target price of $60, about 8% below recent levels. He noted that his five-year financial forecasts on the company are “broadly below current consensus estimates.” He thinks the company will fall short of Twitter’s own user and revenue goals laid out at its February 2021 analyst day.\nOn Airbnb, Sheridan’s price target is $132, which implies about a 20% drop from recent levels. Sheridan said the company is “a strong player with runway for growth and margin expansion,” but he also expects “a volatile travel environment ahead,” finds the online travel market to be “relatively mature,” and sees “high levels of competitive intensity.” He added that his forward estimates are well below Street estimates.\nAs part of the note, Sheridan laid out a list of 10 themes he sees for the internet group: blurring lines between e-commerce and advertising; the rise of the creator economy; streaming media reaching global scale, but with content cost questions; the shift of local commerce online; the growth of subscription-based services, but with potential consumer fatigue; the growth of cloud computing; the emergence of augmented reality and the metaverse; more personalized online travel services; growing costs from regulation; and the rise of the decentralized web.","news_type":1},"isVote":1,"tweetType":1,"viewCount":418,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":886059810,"gmtCreate":1631540494730,"gmtModify":1676530570081,"author":{"id":"3556954148323654","authorId":"3556954148323654","name":"cart158","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3556954148323654","authorIdStr":"3556954148323654"},"themes":[],"htmlText":"Good good","listText":"Good good","text":"Good good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/886059810","repostId":"2167583295","repostType":4,"isVote":1,"tweetType":1,"viewCount":266,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":897070590,"gmtCreate":1628865134010,"gmtModify":1676529880184,"author":{"id":"3556954148323654","authorId":"3556954148323654","name":"cart158","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3556954148323654","authorIdStr":"3556954148323654"},"themes":[],"htmlText":"I wonder the whole world have enough vivid vaccine or not","listText":"I wonder the whole world have enough vivid vaccine or not","text":"I wonder the whole world have enough vivid vaccine or not","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/897070590","repostId":"1121308321","repostType":4,"repost":{"id":"1121308321","pubTimestamp":1628859436,"share":"https://ttm.financial/m/news/1121308321?lang=&edition=fundamental","pubTime":"2021-08-13 20:57","market":"us","language":"en","title":"Americans With Weak Immune Systems Will Get 3 Covid Shots","url":"https://stock-news.laohu8.com/highlight/detail?id=1121308321","media":"Bloomberg","summary":"Americans with weakened immune systems will be allowed to get three shots of Covid-19 vaccine after ","content":"<p>Americans with weakened immune systems will be allowed to get three shots of Covid-19 vaccine after U.S. regulators authorized giving an extra dose to the most vulnerable people.</p>\n<p>The U.S. Food and Drug Administration’s action expands the use of vaccines fromModerna Inc.and the partnership ofPfizer Inc.andBioNTech SEfor organ transplant recipients and patients with other conditions like cancer that hobble the body’s natural infection-fighting response. The decision doesn’t apply to other fully vaccinated individuals, the agency said in astatement.</p>\n<p>The U.S. is currently facing a surge of infections spawned by the highly infectious delta variant, with more than 117,000 new cases diagnosed yesterday. The FDA’s move was designed to protect those people most likely to be harmed or die from an infection, even after a standard course of shots.</p>\n<p>“The country has entered yet another wave of the Covid-19 pandemic, and the FDA is especially cognizant that immunocompromised people are particularly at risk for severe disease,” said Acting Commissioner Janet Woodcock. “After a thorough review of the available data, the FDA determined that this small, vulnerable group may benefit from a third dose of the Pfizer-BioNTech or Moderna vaccines.”</p>\n<p>Vaccine Access</p>\n<p>The decision could further exacerbate the vaccine inequality that exists across the world. The U.S. is joining countries including Israel, Germany and France in offering boosters to vulnerable groups, while nations including Russia and the United Arab Emirates are giving them even more broadly. The European Union’s drugs regulatorsaidFriday that it’s coordinating with vaccine makers and reviewing data on third shots.</p>\n<p>Meanwhile, dozens of countries have such limited access to the vaccines that they have immunized fewer than 10% of their populations.</p>\n<p>The FDA’s decision was supported by a study published in the New England Journal of Medicine on Wednesday, showing that a third dose of Moderna’s vaccine significantly raised levels of Covid-fighting antibodies in 55% of transplant patients. Among those who got a placebo rather than the extra shot, just 18% generated the desired antibody levels, thestudyfound.</p>\n<p>“Ifeelvery relieved that they are doing this, because it will save lives,” said Janet Handal, a kidney transplant recipient. “I wish that they had done it sooner.”</p>\n<p>While the U.S.-authorized Covid-19 vaccines are highly effective at preventing severe disease, hospitalization and death in most people, booster shots are especially important for transplant patients and others with weak immune systems, who often don’t get adequate responses to their first vaccine course. Immune compromised people compose about 3% of adults, Rochelle Walensky, director of the Centers for Disease Control and Prevention, said on a press call.</p>\n<p>Many patients had sought out extra doses on their own as findings emerged on their responses to vaccines. Dorry Segev, a professor of surgery and epidemiology at Johns Hopkins University, said his research team has observed more than 200 transplant recipients who have gotten third shots, and he suspects many more immunocompromised patients have done so as well.</p>\n<p>Advisers for the CDC raised concerns at a meeting last month about patients getting additional doses in an unsupervised manner and the inequities that could arise.</p>\n<p>“The people who’ve gotten it now are the people who navigate the health care system well, who are willing to go to great lengths,” Segev said. FDA approval “would then expand access of these boosters in a more equitable way to people who might not be as good as navigating the health care system and might have been too shy or too worried about pursuing something.”</p>\n<p>The FDA’s action allows for a third shot at least 28 days after the initial two-dose regimen in organ transplant recipients and patients with conditions “considered to have an equivalent level of immunocompromise.” Immune compromising conditions include blood cancers, HIV, multiple sclerosis and many others. In some cases, patients’ conditions weaken the immune system; in others, it’s their medications. Among the various conditions, the degree of immune suppression may differ.</p>\n<p>Not all patients may develop an antibody response after the third dose, as research so far has shown. Until there’s more information about how much protection patients have after a third dose and until the delta wave subsides, patients should still continue to mask and social distance, Segev said.</p>\n<p>Only those with weakened immune systems will be offered boosters, White House chief medical adviser Anthony Fauci said on NBC’s ”Today” show. For other vaccinated groups, such as the elderly, data is being collected to determine if or when their protection goes “below a critical level.”</p>\n<p>“Right now at this moment, other than the immune-compromised, we’re not going to be giving boosters to people, but we will be following them very carefully, and if they do need it, we’ll be ready to give it to them,” he said.</p>\n<p>About 60% of eligible Americans, age 12 and older, are fully vaccinated, according to the CDC. And while the pace of immunization is rising after falling sharply from a high point in mid-April, the Biden administration is urging people to get shots as infections surge in the U.S., fueled by the delta variant.</p>\n<p>An advisory committee to the CDC is also set to discuss booster doses of Covid–19 vaccine for immunocompromised patients on Friday.</p>\n<p>Handal and other transplant recipients formed Transplant Recipients and Immunocompromised Patient Advocacy Group during the pandemic that has urged the FDA to streamline approval of additional doses for those with weakened immune systems.</p>\n<p>“People that are immunocompromised are continuing to live with the fear that everyonefeltin the early days of Covid,” Handal said in an interview. They’re carrying on with their lives as the world opens up, but “it’s just an undercurrent of fear, and it’s exhausting to live with.”</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Americans With Weak Immune Systems Will Get 3 Covid Shots</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmericans With Weak Immune Systems Will Get 3 Covid Shots\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-13 20:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-13/u-s-clears-third-covid-shot-for-immunocompromised-patients><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Americans with weakened immune systems will be allowed to get three shots of Covid-19 vaccine after U.S. regulators authorized giving an extra dose to the most vulnerable people.\nThe U.S. Food and ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-13/u-s-clears-third-covid-shot-for-immunocompromised-patients\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-08-13/u-s-clears-third-covid-shot-for-immunocompromised-patients","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1121308321","content_text":"Americans with weakened immune systems will be allowed to get three shots of Covid-19 vaccine after U.S. regulators authorized giving an extra dose to the most vulnerable people.\nThe U.S. Food and Drug Administration’s action expands the use of vaccines fromModerna Inc.and the partnership ofPfizer Inc.andBioNTech SEfor organ transplant recipients and patients with other conditions like cancer that hobble the body’s natural infection-fighting response. The decision doesn’t apply to other fully vaccinated individuals, the agency said in astatement.\nThe U.S. is currently facing a surge of infections spawned by the highly infectious delta variant, with more than 117,000 new cases diagnosed yesterday. The FDA’s move was designed to protect those people most likely to be harmed or die from an infection, even after a standard course of shots.\n“The country has entered yet another wave of the Covid-19 pandemic, and the FDA is especially cognizant that immunocompromised people are particularly at risk for severe disease,” said Acting Commissioner Janet Woodcock. “After a thorough review of the available data, the FDA determined that this small, vulnerable group may benefit from a third dose of the Pfizer-BioNTech or Moderna vaccines.”\nVaccine Access\nThe decision could further exacerbate the vaccine inequality that exists across the world. The U.S. is joining countries including Israel, Germany and France in offering boosters to vulnerable groups, while nations including Russia and the United Arab Emirates are giving them even more broadly. The European Union’s drugs regulatorsaidFriday that it’s coordinating with vaccine makers and reviewing data on third shots.\nMeanwhile, dozens of countries have such limited access to the vaccines that they have immunized fewer than 10% of their populations.\nThe FDA’s decision was supported by a study published in the New England Journal of Medicine on Wednesday, showing that a third dose of Moderna’s vaccine significantly raised levels of Covid-fighting antibodies in 55% of transplant patients. Among those who got a placebo rather than the extra shot, just 18% generated the desired antibody levels, thestudyfound.\n“Ifeelvery relieved that they are doing this, because it will save lives,” said Janet Handal, a kidney transplant recipient. “I wish that they had done it sooner.”\nWhile the U.S.-authorized Covid-19 vaccines are highly effective at preventing severe disease, hospitalization and death in most people, booster shots are especially important for transplant patients and others with weak immune systems, who often don’t get adequate responses to their first vaccine course. Immune compromised people compose about 3% of adults, Rochelle Walensky, director of the Centers for Disease Control and Prevention, said on a press call.\nMany patients had sought out extra doses on their own as findings emerged on their responses to vaccines. Dorry Segev, a professor of surgery and epidemiology at Johns Hopkins University, said his research team has observed more than 200 transplant recipients who have gotten third shots, and he suspects many more immunocompromised patients have done so as well.\nAdvisers for the CDC raised concerns at a meeting last month about patients getting additional doses in an unsupervised manner and the inequities that could arise.\n“The people who’ve gotten it now are the people who navigate the health care system well, who are willing to go to great lengths,” Segev said. FDA approval “would then expand access of these boosters in a more equitable way to people who might not be as good as navigating the health care system and might have been too shy or too worried about pursuing something.”\nThe FDA’s action allows for a third shot at least 28 days after the initial two-dose regimen in organ transplant recipients and patients with conditions “considered to have an equivalent level of immunocompromise.” Immune compromising conditions include blood cancers, HIV, multiple sclerosis and many others. In some cases, patients’ conditions weaken the immune system; in others, it’s their medications. Among the various conditions, the degree of immune suppression may differ.\nNot all patients may develop an antibody response after the third dose, as research so far has shown. Until there’s more information about how much protection patients have after a third dose and until the delta wave subsides, patients should still continue to mask and social distance, Segev said.\nOnly those with weakened immune systems will be offered boosters, White House chief medical adviser Anthony Fauci said on NBC’s ”Today” show. For other vaccinated groups, such as the elderly, data is being collected to determine if or when their protection goes “below a critical level.”\n“Right now at this moment, other than the immune-compromised, we’re not going to be giving boosters to people, but we will be following them very carefully, and if they do need it, we’ll be ready to give it to them,” he said.\nAbout 60% of eligible Americans, age 12 and older, are fully vaccinated, according to the CDC. And while the pace of immunization is rising after falling sharply from a high point in mid-April, the Biden administration is urging people to get shots as infections surge in the U.S., fueled by the delta variant.\nAn advisory committee to the CDC is also set to discuss booster doses of Covid–19 vaccine for immunocompromised patients on Friday.\nHandal and other transplant recipients formed Transplant Recipients and Immunocompromised Patient Advocacy Group during the pandemic that has urged the FDA to streamline approval of additional doses for those with weakened immune systems.\n“People that are immunocompromised are continuing to live with the fear that everyonefeltin the early days of Covid,” Handal said in an interview. They’re carrying on with their lives as the world opens up, but “it’s just an undercurrent of fear, and it’s exhausting to live with.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":216,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":894740335,"gmtCreate":1628859995827,"gmtModify":1676529877286,"author":{"id":"3556954148323654","authorId":"3556954148323654","name":"cart158","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3556954148323654","authorIdStr":"3556954148323654"},"themes":[],"htmlText":"Time to buy now? How?","listText":"Time to buy now? How?","text":"Time to buy now? How?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/894740335","repostId":"2159829435","repostType":4,"repost":{"id":"2159829435","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628852688,"share":"https://ttm.financial/m/news/2159829435?lang=&edition=fundamental","pubTime":"2021-08-13 19:04","market":"us","language":"en","title":"Recap: Jaguar Health Q2 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2159829435","media":"Benzinga","summary":" \n\nShares of Jaguar Health (NASDAQ:JAGX) moved higher by 1.5% in pre-market trading after the company reported Q2 results.\n\nQuarterly Results\n\nEarnings per share rose 77.27% year over year to ($0.10), which missed the estimate of ($0.03).","content":"<p>Shares of <b>Jaguar Health</b> (NASDAQ:JAGX) moved higher by 1.5% in pre-market trading after the company reported Q2 results.</p>\n<h2>Quarterly Results</h2>\n<p>Earnings per share rose 77.27% year over year to ($0.10), which missed the estimate of ($0.03).</p>\n<p>Revenue of $385,000 declined by 87.84% from the same period last year, which missed the estimate of $7,280,000.</p>\n<h2>Guidance</h2>\n<p>Jaguar Health hasn't issued any earnings guidance for the time being.</p>\n<p>Revenue guidance hasn't been issued by the company for now.</p>\n<h2>Details Of The Call</h2>\n<p>Date: Aug 13, 2021</p>\n<p>Time: 08:00 AM</p>\n<p>ET Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1487163&amp;tp_key=b3a06aa039</p>\n<h2>Recent Stock Performance</h2>\n<p>Company's 52-week high was at $4.47</p>\n<p>52-week low: $0.18</p>\n<p>Price action over last quarter: Up 8.87%</p>\n<h2>Company Profile</h2>\n<p>Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Recap: Jaguar Health Q2 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRecap: Jaguar Health Q2 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-13 19:04</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>Jaguar Health</b> (NASDAQ:JAGX) moved higher by 1.5% in pre-market trading after the company reported Q2 results.</p>\n<h2>Quarterly Results</h2>\n<p>Earnings per share rose 77.27% year over year to ($0.10), which missed the estimate of ($0.03).</p>\n<p>Revenue of $385,000 declined by 87.84% from the same period last year, which missed the estimate of $7,280,000.</p>\n<h2>Guidance</h2>\n<p>Jaguar Health hasn't issued any earnings guidance for the time being.</p>\n<p>Revenue guidance hasn't been issued by the company for now.</p>\n<h2>Details Of The Call</h2>\n<p>Date: Aug 13, 2021</p>\n<p>Time: 08:00 AM</p>\n<p>ET Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1487163&amp;tp_key=b3a06aa039</p>\n<h2>Recent Stock Performance</h2>\n<p>Company's 52-week high was at $4.47</p>\n<p>52-week low: $0.18</p>\n<p>Price action over last quarter: Up 8.87%</p>\n<h2>Company Profile</h2>\n<p>Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JAGX":"Jaguar Animal Health, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2159829435","content_text":"Shares of Jaguar Health (NASDAQ:JAGX) moved higher by 1.5% in pre-market trading after the company reported Q2 results.\nQuarterly Results\nEarnings per share rose 77.27% year over year to ($0.10), which missed the estimate of ($0.03).\nRevenue of $385,000 declined by 87.84% from the same period last year, which missed the estimate of $7,280,000.\nGuidance\nJaguar Health hasn't issued any earnings guidance for the time being.\nRevenue guidance hasn't been issued by the company for now.\nDetails Of The Call\nDate: Aug 13, 2021\nTime: 08:00 AM\nET Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1487163&tp_key=b3a06aa039\nRecent Stock Performance\nCompany's 52-week high was at $4.47\n52-week low: $0.18\nPrice action over last quarter: Up 8.87%\nCompany Profile\nJaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders.","news_type":1},"isVote":1,"tweetType":1,"viewCount":212,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":894757047,"gmtCreate":1628859939689,"gmtModify":1676529877261,"author":{"id":"3556954148323654","authorId":"3556954148323654","name":"cart158","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3556954148323654","authorIdStr":"3556954148323654"},"themes":[],"htmlText":"Good good","listText":"Good good","text":"Good good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/894757047","repostId":"1121308321","repostType":4,"repost":{"id":"1121308321","pubTimestamp":1628859436,"share":"https://ttm.financial/m/news/1121308321?lang=&edition=fundamental","pubTime":"2021-08-13 20:57","market":"us","language":"en","title":"Americans With Weak Immune Systems Will Get 3 Covid Shots","url":"https://stock-news.laohu8.com/highlight/detail?id=1121308321","media":"Bloomberg","summary":"Americans with weakened immune systems will be allowed to get three shots of Covid-19 vaccine after ","content":"<p>Americans with weakened immune systems will be allowed to get three shots of Covid-19 vaccine after U.S. regulators authorized giving an extra dose to the most vulnerable people.</p>\n<p>The U.S. Food and Drug Administration’s action expands the use of vaccines fromModerna Inc.and the partnership ofPfizer Inc.andBioNTech SEfor organ transplant recipients and patients with other conditions like cancer that hobble the body’s natural infection-fighting response. The decision doesn’t apply to other fully vaccinated individuals, the agency said in astatement.</p>\n<p>The U.S. is currently facing a surge of infections spawned by the highly infectious delta variant, with more than 117,000 new cases diagnosed yesterday. The FDA’s move was designed to protect those people most likely to be harmed or die from an infection, even after a standard course of shots.</p>\n<p>“The country has entered yet another wave of the Covid-19 pandemic, and the FDA is especially cognizant that immunocompromised people are particularly at risk for severe disease,” said Acting Commissioner Janet Woodcock. “After a thorough review of the available data, the FDA determined that this small, vulnerable group may benefit from a third dose of the Pfizer-BioNTech or Moderna vaccines.”</p>\n<p>Vaccine Access</p>\n<p>The decision could further exacerbate the vaccine inequality that exists across the world. The U.S. is joining countries including Israel, Germany and France in offering boosters to vulnerable groups, while nations including Russia and the United Arab Emirates are giving them even more broadly. The European Union’s drugs regulatorsaidFriday that it’s coordinating with vaccine makers and reviewing data on third shots.</p>\n<p>Meanwhile, dozens of countries have such limited access to the vaccines that they have immunized fewer than 10% of their populations.</p>\n<p>The FDA’s decision was supported by a study published in the New England Journal of Medicine on Wednesday, showing that a third dose of Moderna’s vaccine significantly raised levels of Covid-fighting antibodies in 55% of transplant patients. Among those who got a placebo rather than the extra shot, just 18% generated the desired antibody levels, thestudyfound.</p>\n<p>“Ifeelvery relieved that they are doing this, because it will save lives,” said Janet Handal, a kidney transplant recipient. “I wish that they had done it sooner.”</p>\n<p>While the U.S.-authorized Covid-19 vaccines are highly effective at preventing severe disease, hospitalization and death in most people, booster shots are especially important for transplant patients and others with weak immune systems, who often don’t get adequate responses to their first vaccine course. Immune compromised people compose about 3% of adults, Rochelle Walensky, director of the Centers for Disease Control and Prevention, said on a press call.</p>\n<p>Many patients had sought out extra doses on their own as findings emerged on their responses to vaccines. Dorry Segev, a professor of surgery and epidemiology at Johns Hopkins University, said his research team has observed more than 200 transplant recipients who have gotten third shots, and he suspects many more immunocompromised patients have done so as well.</p>\n<p>Advisers for the CDC raised concerns at a meeting last month about patients getting additional doses in an unsupervised manner and the inequities that could arise.</p>\n<p>“The people who’ve gotten it now are the people who navigate the health care system well, who are willing to go to great lengths,” Segev said. FDA approval “would then expand access of these boosters in a more equitable way to people who might not be as good as navigating the health care system and might have been too shy or too worried about pursuing something.”</p>\n<p>The FDA’s action allows for a third shot at least 28 days after the initial two-dose regimen in organ transplant recipients and patients with conditions “considered to have an equivalent level of immunocompromise.” Immune compromising conditions include blood cancers, HIV, multiple sclerosis and many others. In some cases, patients’ conditions weaken the immune system; in others, it’s their medications. Among the various conditions, the degree of immune suppression may differ.</p>\n<p>Not all patients may develop an antibody response after the third dose, as research so far has shown. Until there’s more information about how much protection patients have after a third dose and until the delta wave subsides, patients should still continue to mask and social distance, Segev said.</p>\n<p>Only those with weakened immune systems will be offered boosters, White House chief medical adviser Anthony Fauci said on NBC’s ”Today” show. For other vaccinated groups, such as the elderly, data is being collected to determine if or when their protection goes “below a critical level.”</p>\n<p>“Right now at this moment, other than the immune-compromised, we’re not going to be giving boosters to people, but we will be following them very carefully, and if they do need it, we’ll be ready to give it to them,” he said.</p>\n<p>About 60% of eligible Americans, age 12 and older, are fully vaccinated, according to the CDC. And while the pace of immunization is rising after falling sharply from a high point in mid-April, the Biden administration is urging people to get shots as infections surge in the U.S., fueled by the delta variant.</p>\n<p>An advisory committee to the CDC is also set to discuss booster doses of Covid–19 vaccine for immunocompromised patients on Friday.</p>\n<p>Handal and other transplant recipients formed Transplant Recipients and Immunocompromised Patient Advocacy Group during the pandemic that has urged the FDA to streamline approval of additional doses for those with weakened immune systems.</p>\n<p>“People that are immunocompromised are continuing to live with the fear that everyonefeltin the early days of Covid,” Handal said in an interview. They’re carrying on with their lives as the world opens up, but “it’s just an undercurrent of fear, and it’s exhausting to live with.”</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Americans With Weak Immune Systems Will Get 3 Covid Shots</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmericans With Weak Immune Systems Will Get 3 Covid Shots\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-13 20:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-13/u-s-clears-third-covid-shot-for-immunocompromised-patients><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Americans with weakened immune systems will be allowed to get three shots of Covid-19 vaccine after U.S. regulators authorized giving an extra dose to the most vulnerable people.\nThe U.S. Food and ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-13/u-s-clears-third-covid-shot-for-immunocompromised-patients\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-08-13/u-s-clears-third-covid-shot-for-immunocompromised-patients","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1121308321","content_text":"Americans with weakened immune systems will be allowed to get three shots of Covid-19 vaccine after U.S. regulators authorized giving an extra dose to the most vulnerable people.\nThe U.S. Food and Drug Administration’s action expands the use of vaccines fromModerna Inc.and the partnership ofPfizer Inc.andBioNTech SEfor organ transplant recipients and patients with other conditions like cancer that hobble the body’s natural infection-fighting response. The decision doesn’t apply to other fully vaccinated individuals, the agency said in astatement.\nThe U.S. is currently facing a surge of infections spawned by the highly infectious delta variant, with more than 117,000 new cases diagnosed yesterday. The FDA’s move was designed to protect those people most likely to be harmed or die from an infection, even after a standard course of shots.\n“The country has entered yet another wave of the Covid-19 pandemic, and the FDA is especially cognizant that immunocompromised people are particularly at risk for severe disease,” said Acting Commissioner Janet Woodcock. “After a thorough review of the available data, the FDA determined that this small, vulnerable group may benefit from a third dose of the Pfizer-BioNTech or Moderna vaccines.”\nVaccine Access\nThe decision could further exacerbate the vaccine inequality that exists across the world. The U.S. is joining countries including Israel, Germany and France in offering boosters to vulnerable groups, while nations including Russia and the United Arab Emirates are giving them even more broadly. The European Union’s drugs regulatorsaidFriday that it’s coordinating with vaccine makers and reviewing data on third shots.\nMeanwhile, dozens of countries have such limited access to the vaccines that they have immunized fewer than 10% of their populations.\nThe FDA’s decision was supported by a study published in the New England Journal of Medicine on Wednesday, showing that a third dose of Moderna’s vaccine significantly raised levels of Covid-fighting antibodies in 55% of transplant patients. Among those who got a placebo rather than the extra shot, just 18% generated the desired antibody levels, thestudyfound.\n“Ifeelvery relieved that they are doing this, because it will save lives,” said Janet Handal, a kidney transplant recipient. “I wish that they had done it sooner.”\nWhile the U.S.-authorized Covid-19 vaccines are highly effective at preventing severe disease, hospitalization and death in most people, booster shots are especially important for transplant patients and others with weak immune systems, who often don’t get adequate responses to their first vaccine course. Immune compromised people compose about 3% of adults, Rochelle Walensky, director of the Centers for Disease Control and Prevention, said on a press call.\nMany patients had sought out extra doses on their own as findings emerged on their responses to vaccines. Dorry Segev, a professor of surgery and epidemiology at Johns Hopkins University, said his research team has observed more than 200 transplant recipients who have gotten third shots, and he suspects many more immunocompromised patients have done so as well.\nAdvisers for the CDC raised concerns at a meeting last month about patients getting additional doses in an unsupervised manner and the inequities that could arise.\n“The people who’ve gotten it now are the people who navigate the health care system well, who are willing to go to great lengths,” Segev said. FDA approval “would then expand access of these boosters in a more equitable way to people who might not be as good as navigating the health care system and might have been too shy or too worried about pursuing something.”\nThe FDA’s action allows for a third shot at least 28 days after the initial two-dose regimen in organ transplant recipients and patients with conditions “considered to have an equivalent level of immunocompromise.” Immune compromising conditions include blood cancers, HIV, multiple sclerosis and many others. In some cases, patients’ conditions weaken the immune system; in others, it’s their medications. Among the various conditions, the degree of immune suppression may differ.\nNot all patients may develop an antibody response after the third dose, as research so far has shown. Until there’s more information about how much protection patients have after a third dose and until the delta wave subsides, patients should still continue to mask and social distance, Segev said.\nOnly those with weakened immune systems will be offered boosters, White House chief medical adviser Anthony Fauci said on NBC’s ”Today” show. For other vaccinated groups, such as the elderly, data is being collected to determine if or when their protection goes “below a critical level.”\n“Right now at this moment, other than the immune-compromised, we’re not going to be giving boosters to people, but we will be following them very carefully, and if they do need it, we’ll be ready to give it to them,” he said.\nAbout 60% of eligible Americans, age 12 and older, are fully vaccinated, according to the CDC. And while the pace of immunization is rising after falling sharply from a high point in mid-April, the Biden administration is urging people to get shots as infections surge in the U.S., fueled by the delta variant.\nAn advisory committee to the CDC is also set to discuss booster doses of Covid–19 vaccine for immunocompromised patients on Friday.\nHandal and other transplant recipients formed Transplant Recipients and Immunocompromised Patient Advocacy Group during the pandemic that has urged the FDA to streamline approval of additional doses for those with weakened immune systems.\n“People that are immunocompromised are continuing to live with the fear that everyonefeltin the early days of Covid,” Handal said in an interview. They’re carrying on with their lives as the world opens up, but “it’s just an undercurrent of fear, and it’s exhausting to live with.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":172,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":832422376,"gmtCreate":1629675881195,"gmtModify":1676530090245,"author":{"id":"3556954148323654","authorId":"3556954148323654","name":"cart158","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3556954148323654","authorIdStr":"3556954148323654"},"themes":[],"htmlText":"want sell now?","listText":"want sell now?","text":"want sell now?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/832422376","repostId":"838742907","repostType":1,"repost":{"id":838742907,"gmtCreate":1629432482109,"gmtModify":1676530039665,"author":{"id":"3582706821016791","authorId":"3582706821016791","name":"Goh Tang Peng","avatar":"https://community-static.tradeup.com/news/bff59b5e90b9a1db84eedde04d8851b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582706821016791","authorIdStr":"3582706821016791"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/HST.SI\">$Lion-OCBC Sec HSTECH S$(HST.SI)$</a>&nbsp;die la die la, regretted buying, HK market look so weak again and again,&nbsp;may go down further&nbsp;to $0.850 hsien ah hsien ah.&nbsp;","listText":"<a href=\"https://laohu8.com/S/HST.SI\">$Lion-OCBC Sec HSTECH S$(HST.SI)$</a>&nbsp;die la die la, regretted buying, HK market look so weak again and again,&nbsp;may go down further&nbsp;to $0.850 hsien ah hsien ah.&nbsp;","text":"$Lion-OCBC Sec HSTECH S$(HST.SI)$ die la die la, regretted buying, HK market look so weak again and again, may go down further to $0.850 hsien ah hsien ah.","images":[{"img":"https://static.tigerbbs.com/49da47558038f7eff00e37570a3c0012","width":"1080","height":"1920"}],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/838742907","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":453,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":805072231,"gmtCreate":1627829678423,"gmtModify":1703496365242,"author":{"id":"3556954148323654","authorId":"3556954148323654","name":"cart158","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3556954148323654","authorIdStr":"3556954148323654"},"themes":[],"htmlText":"Hope it's become better","listText":"Hope it's become better","text":"Hope it's become better","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/805072231","repostId":"1138566016","repostType":4,"repost":{"id":"1138566016","pubTimestamp":1627689251,"share":"https://ttm.financial/m/news/1138566016?lang=&edition=fundamental","pubTime":"2021-07-31 07:54","market":"us","language":"en","title":"It’s Open Season on Closed-End Fund Activists. How Fund Holders Can Win—and Lose","url":"https://stock-news.laohu8.com/highlight/detail?id=1138566016","media":"Barron's","summary":"TheTempleton Global Incomefund frustrated investors for years. Despite star manager Michael Hasensta","content":"<p>TheTempleton Global Incomefund frustrated investors for years. Despite star manager Michael Hasenstab at the helm, the closed-end fund returned an average of 0.3% annually in the past decade, versus an average 7% for peers in global income. Also frustrating, its shares rarely traded close to the fund’s underlying net asset value, or NAV. The discount averaged 11% in the past three years.</p>\n<p>Investors have caught a break, however, thanks to Saba Capital Management, a hedge fund shop run by activist investor Boaz Weinstein. Saba amassed a 20% stake in the Templeton fund and recently won four contested board seats. It has been pressuring the board to take actions to boost the share price. Its moves have paid off: The fund has returned a total 4.5% this year as its share price improved, and the discount to NAV has shrunk to 4%.</p>\n<p>Tactics like Saba’s have long infuriated mutual fund companies; no one wants a hedge fund threatening a coup. Now, with some help from Congress, the playing field could tilt in favor of closed-end funds and their company sponsors, due to a bill recently introduced in the House. That could work against the interests of fund investors.</p>\n<p>The Increasing Investor Opportunities Act, introduced in June by Rep. Anthony Gonzalez (R., Ohio) and Rep. Gregory Meeks (D., New York), includes two measures that could make it much tougher for hedge funds to pressure closed-end funds and win proxy fights. One proposed change would lift the current 15% limit on closed-end-fund ownership of illiquid private funds, such as venture-capital and private-equity funds. A second measure would prevent activist hedge funds from acquiring more than 10% of a closed-end fund’s shares.</p>\n<p>A spokesman for Gonzalez declined to comment. Meeks didn’t respond to requests for comment.</p>\n<p>Proponents of the changes say they would expand access to private markets for retail investors. They also say hedge funds are exploiting gaps in securities laws at a cost to long-term shareholders, saddling them with tax liabilities, higher fees, and forced fund liquidations. The bill would eliminate a “loophole that activist investors have used to extract short-term profits at the expense of retail investors,” the Investment Company Institute, or ICI, said in a recent statement.</p>\n<p>Hedge funds and portfolio managers who invest in closed-end funds say that mutual fund companies are simply trying to protect a pool of assets and fees from shareholder interference. Most retail investors don’t vote their shares in proxy contests. That may leave fund boards largely free to pursue their own agendas.</p>\n<p>“Activism plays an important role, and if this bill passes, it will become more difficult for activists to threaten or create changes,” says Matt Buffington, a portfolio manager at Dryden Capital, an activist hedge fund.</p>\n<p>Gregory Neer, a portfolio manager with Relative Value Partners, an advisory firm that invests in closed-end funds, agrees. “The ability for investors to pressure funds is beneficial to all shareholders,” he says.</p>\n<p>Closed-end funds have long been popular with investors due to their high yields and steady distributions. Many use leverage, borrowing money at market rates to boost payouts. They also generate income with options strategies and investments in high-yielding areas of the stock and bond markets.</p>\n<p>But the funds have structural drawbacks. Expense ratios are steep, averaging 2.1%, according to Morningstar Direct. And since the funds have a fixed number of shares outstanding, prices reflect market demand for both a fund and its underlying assets. Funds usually trade at a discount to NAV. While it is attractive, in theory, to pay 90 cents for a dollar of assets, investors might never see the extra dime.</p>\n<p>Hedge funds aim to exploit this inefficiency, buying closed-end funds at below-market value. They then pressure fund boards to take steps to lift the funds’ prices. The playbook is straightforward: accumulate a stake, win board seats, and then force a fund company into a tender offer, whereby it agrees to repurchase shares at nearly full price.</p>\n<p>If that fails, a hedge fund might try to replace a fund’s manager, orchestrate a liquidation of the fund, or get it converted to an open-end fund—moves that could also pay off with the share price rising to parity with the NAV. Firms like Saba have also taken over funds entirely.</p>\n<p>Giving closed-end funds freedom to own more private securities could throw a wrench into the strategy. Tender offers work only if a fund can liquidate most of its holdings at market prices. Because venture-capital and private-equity holdings generally don’t trade publicly, their pricing isn’t transparent. “When closed-end funds invest in illiquid things, it protects them from activism,” one activist manager tells<i>Barron’s</i>.</p>\n<p>Removing the cap on private-fund ownership is “in line with a legislative agenda of getting retail investors more access to private investments,” says Thomas DeCapo, an attorney for the mutual fund industry.</p>\n<p>And capping activists at 10% of a fund doesn’t stop them from mounting proxy campaigns. “Nothing about this is antidemocratic,” he says. “It doesn’t stop a majority of investors who are unhappy or want change. It stops one investor from using its economic power, with other people’s money, to basically force changes on everybody else.”</p>\n<p>Investor advocates see it differently, however, saying fund investors could wind up paying higher fees for funds that hold more-opaque investments. “It’s just another fund-of-funds structure, and those are notoriously high-fee,” says Tyler Gellasch, head of Healthy Markets, an investor-protection group.</p>\n<p>Individual hedge funds technically can’t own more than 3% of a closed-end fund, under ownership restrictions in the Investment Company Act of 1940. But they skirt the rule by building stakes through affiliated entities, creating enough of a critical mass to force changes at a fund through proxy voting.</p>\n<p>The ICI—the mutual fund industry’s lobby—has tried to persuade regulators to crack down on hedge funds. In a submission to the Securities and Exchange Commission last year, the ICI argued that hedge fund campaigns often consume a fund’s resources, trigger tax liabilities for long-term investors, and result in the forced selling of securities to meet a hedge fund’s demands for a tender offer. A fund’s expense ratio could increase if it is forced to buy back shares and its asset base shrinks.</p>\n<p>The activist community’s “assault” on the industry has had a chilling effect on product launches, the ICI said, resulting in fewer closed-end funds on the market today than in 2007.</p>\n<p>But hedge funds argue that changing the 1940 act would amount to a power grab by mutual funds. “This is all coming from the mutual fund industry, and it’s no coincidence that this protects them,” says Phil Goldstein, co-founder of Bulldog Investors, an activist that has long targeted closed-end funds. “There are funds with terrible performance and wide discounts. The ICI never says we need a mechanism where shareholders can hold those managers accountable.”</p>\n<p>Imposing an ownership cap would also make proxy campaigns less economic. Limited to 10%, hedge funds wouldn’t own enough shares, with sufficient economic interest, to justify the expense of a proxy contest, which can cost millions of dollars. “If you’re limited to 10% and have to spend 2.5% of your assets on a proxy campaign, you’d say it’s too risky,” says Goldstein. “Meanwhile, management isn’t spending anything—just shareholder money. They want to make it economically unattractive to run a proxy contest.”</p>\n<p>Regulators and courts have expressed skepticism about some defenses that closed-end funds have adopted to prevent shareholder challenges. And, the SEC might not side with the fund industry. Since 2010, the SEC has warned fund companies against using state securities laws to thwart hedge fund takeovers. The SEC dropped its objection to these state “control share” laws last year under its Republican chairman, Jay Clayton. But the new, Democratic chairman, Gary Gensler, might reinstate the SEC’s objection—a reason for the industry to enlist Congress to change the law. The SEC didn’t respond to requests for comment.</p>\n<p>Institutional Shareholder Services,a firm that makes recommendations on proxy voting, says investors should reject fund companies’ use of state control-share laws, which limit the voting rights of shareholders. With the SEC on the sidelines, ISS says, “CEF shareholders are denied important voting rights and are subject to management entrenchment.”</p>\n<p><img src=\"https://static.tigerbbs.com/70323ed9daef142f19afd48be72b6299\" tg-width=\"755\" tg-height=\"334\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/68beb47d59eb02e90b04eb7093f9f17b\" tg-width=\"759\" tg-height=\"285\" referrerpolicy=\"no-referrer\">Hedge funds don’t always win, but investors might want to ride along as activists build a stake. “When an activist comes in, you usually see an increase in the share price and a decrease in the discount,” says Matt Souther, an associate finance professor at the University of South Carolina.</p>\n<p>Templeton Global Income’s (ticker: GIM) discount to NAV could narrow further if Saba acquires more shares or tries to take over the fund’s $743 million in assets. Saba recently took over management of another fund, Voya Prime Rate Trust, which it rebrandedSaba Capital Income &amp; Opportunities(BRW).Franklin Templetonand Saba declined to comment.</p>\n<p>Miller/Howard High Income Equity(HIE) is also in Saba’s crosshairs. The fund is a “term trust” with a mandated liquidation date in 2024. It trades at a 5.9% discount to NAV. “In a worst-case scenario, you buy it at a discount and you’ll earn an excess return from now to 2024 because that discount will narrow,” says Patrick Galley, co-manager ofRiverNorth Opportunities(RIV), a closed-end fund that owns HIE.</p>\n<p>Other closed-end funds in which Saba owns stakes includeSource Capital(SOR) andInvesco Dynamic Credit Opportunities(VTA). Bulldog has built a position inTortoise Energy Independence(NDP).</p>\n<p>Some closed-end funds look attractive on their fundamentals.Adams Diversified Equity(ADX) offers exposure to big tech stocks, trades at a 14% discount to NAV, and is committed to an annualized distribution of at least 6%. “For investors who expect tech to do well, ADX is a good holding,” says David Tepper, a closed-end investor and head of Tepper Capital Management in San Francisco.</p>\n<p>Sprott Focus Trust(FUND) is another fund he likes. Veteran small-cap manager Whitney George runs it, and his family owns 45% of the shares. It trades at a 10% discount and yields 5.7%. Tepper also favorsRoyce Global Value Trust(RGT), trading at a 9% discount and yielding 7.9%.</p>\n<p>None of these funds has attracted much activist involvement, according to securities filings. But if activists see opportunity, they could pile in and pressure fund management—assuming that Congress doesn’t rewrite the rules of engagement.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>It’s Open Season on Closed-End Fund Activists. How Fund Holders Can Win—and Lose</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIt’s Open Season on Closed-End Fund Activists. How Fund Holders Can Win—and Lose\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-31 07:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/congress-closed-end-funds-legislation-51627657959?mod=newsviewer_click><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>TheTempleton Global Incomefund frustrated investors for years. Despite star manager Michael Hasenstab at the helm, the closed-end fund returned an average of 0.3% annually in the past decade, versus ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/congress-closed-end-funds-legislation-51627657959?mod=newsviewer_click\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.marketwatch.com/articles/congress-closed-end-funds-legislation-51627657959?mod=newsviewer_click","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138566016","content_text":"TheTempleton Global Incomefund frustrated investors for years. Despite star manager Michael Hasenstab at the helm, the closed-end fund returned an average of 0.3% annually in the past decade, versus an average 7% for peers in global income. Also frustrating, its shares rarely traded close to the fund’s underlying net asset value, or NAV. The discount averaged 11% in the past three years.\nInvestors have caught a break, however, thanks to Saba Capital Management, a hedge fund shop run by activist investor Boaz Weinstein. Saba amassed a 20% stake in the Templeton fund and recently won four contested board seats. It has been pressuring the board to take actions to boost the share price. Its moves have paid off: The fund has returned a total 4.5% this year as its share price improved, and the discount to NAV has shrunk to 4%.\nTactics like Saba’s have long infuriated mutual fund companies; no one wants a hedge fund threatening a coup. Now, with some help from Congress, the playing field could tilt in favor of closed-end funds and their company sponsors, due to a bill recently introduced in the House. That could work against the interests of fund investors.\nThe Increasing Investor Opportunities Act, introduced in June by Rep. Anthony Gonzalez (R., Ohio) and Rep. Gregory Meeks (D., New York), includes two measures that could make it much tougher for hedge funds to pressure closed-end funds and win proxy fights. One proposed change would lift the current 15% limit on closed-end-fund ownership of illiquid private funds, such as venture-capital and private-equity funds. A second measure would prevent activist hedge funds from acquiring more than 10% of a closed-end fund’s shares.\nA spokesman for Gonzalez declined to comment. Meeks didn’t respond to requests for comment.\nProponents of the changes say they would expand access to private markets for retail investors. They also say hedge funds are exploiting gaps in securities laws at a cost to long-term shareholders, saddling them with tax liabilities, higher fees, and forced fund liquidations. The bill would eliminate a “loophole that activist investors have used to extract short-term profits at the expense of retail investors,” the Investment Company Institute, or ICI, said in a recent statement.\nHedge funds and portfolio managers who invest in closed-end funds say that mutual fund companies are simply trying to protect a pool of assets and fees from shareholder interference. Most retail investors don’t vote their shares in proxy contests. That may leave fund boards largely free to pursue their own agendas.\n“Activism plays an important role, and if this bill passes, it will become more difficult for activists to threaten or create changes,” says Matt Buffington, a portfolio manager at Dryden Capital, an activist hedge fund.\nGregory Neer, a portfolio manager with Relative Value Partners, an advisory firm that invests in closed-end funds, agrees. “The ability for investors to pressure funds is beneficial to all shareholders,” he says.\nClosed-end funds have long been popular with investors due to their high yields and steady distributions. Many use leverage, borrowing money at market rates to boost payouts. They also generate income with options strategies and investments in high-yielding areas of the stock and bond markets.\nBut the funds have structural drawbacks. Expense ratios are steep, averaging 2.1%, according to Morningstar Direct. And since the funds have a fixed number of shares outstanding, prices reflect market demand for both a fund and its underlying assets. Funds usually trade at a discount to NAV. While it is attractive, in theory, to pay 90 cents for a dollar of assets, investors might never see the extra dime.\nHedge funds aim to exploit this inefficiency, buying closed-end funds at below-market value. They then pressure fund boards to take steps to lift the funds’ prices. The playbook is straightforward: accumulate a stake, win board seats, and then force a fund company into a tender offer, whereby it agrees to repurchase shares at nearly full price.\nIf that fails, a hedge fund might try to replace a fund’s manager, orchestrate a liquidation of the fund, or get it converted to an open-end fund—moves that could also pay off with the share price rising to parity with the NAV. Firms like Saba have also taken over funds entirely.\nGiving closed-end funds freedom to own more private securities could throw a wrench into the strategy. Tender offers work only if a fund can liquidate most of its holdings at market prices. Because venture-capital and private-equity holdings generally don’t trade publicly, their pricing isn’t transparent. “When closed-end funds invest in illiquid things, it protects them from activism,” one activist manager tellsBarron’s.\nRemoving the cap on private-fund ownership is “in line with a legislative agenda of getting retail investors more access to private investments,” says Thomas DeCapo, an attorney for the mutual fund industry.\nAnd capping activists at 10% of a fund doesn’t stop them from mounting proxy campaigns. “Nothing about this is antidemocratic,” he says. “It doesn’t stop a majority of investors who are unhappy or want change. It stops one investor from using its economic power, with other people’s money, to basically force changes on everybody else.”\nInvestor advocates see it differently, however, saying fund investors could wind up paying higher fees for funds that hold more-opaque investments. “It’s just another fund-of-funds structure, and those are notoriously high-fee,” says Tyler Gellasch, head of Healthy Markets, an investor-protection group.\nIndividual hedge funds technically can’t own more than 3% of a closed-end fund, under ownership restrictions in the Investment Company Act of 1940. But they skirt the rule by building stakes through affiliated entities, creating enough of a critical mass to force changes at a fund through proxy voting.\nThe ICI—the mutual fund industry’s lobby—has tried to persuade regulators to crack down on hedge funds. In a submission to the Securities and Exchange Commission last year, the ICI argued that hedge fund campaigns often consume a fund’s resources, trigger tax liabilities for long-term investors, and result in the forced selling of securities to meet a hedge fund’s demands for a tender offer. A fund’s expense ratio could increase if it is forced to buy back shares and its asset base shrinks.\nThe activist community’s “assault” on the industry has had a chilling effect on product launches, the ICI said, resulting in fewer closed-end funds on the market today than in 2007.\nBut hedge funds argue that changing the 1940 act would amount to a power grab by mutual funds. “This is all coming from the mutual fund industry, and it’s no coincidence that this protects them,” says Phil Goldstein, co-founder of Bulldog Investors, an activist that has long targeted closed-end funds. “There are funds with terrible performance and wide discounts. The ICI never says we need a mechanism where shareholders can hold those managers accountable.”\nImposing an ownership cap would also make proxy campaigns less economic. Limited to 10%, hedge funds wouldn’t own enough shares, with sufficient economic interest, to justify the expense of a proxy contest, which can cost millions of dollars. “If you’re limited to 10% and have to spend 2.5% of your assets on a proxy campaign, you’d say it’s too risky,” says Goldstein. “Meanwhile, management isn’t spending anything—just shareholder money. They want to make it economically unattractive to run a proxy contest.”\nRegulators and courts have expressed skepticism about some defenses that closed-end funds have adopted to prevent shareholder challenges. And, the SEC might not side with the fund industry. Since 2010, the SEC has warned fund companies against using state securities laws to thwart hedge fund takeovers. The SEC dropped its objection to these state “control share” laws last year under its Republican chairman, Jay Clayton. But the new, Democratic chairman, Gary Gensler, might reinstate the SEC’s objection—a reason for the industry to enlist Congress to change the law. The SEC didn’t respond to requests for comment.\nInstitutional Shareholder Services,a firm that makes recommendations on proxy voting, says investors should reject fund companies’ use of state control-share laws, which limit the voting rights of shareholders. With the SEC on the sidelines, ISS says, “CEF shareholders are denied important voting rights and are subject to management entrenchment.”\nHedge funds don’t always win, but investors might want to ride along as activists build a stake. “When an activist comes in, you usually see an increase in the share price and a decrease in the discount,” says Matt Souther, an associate finance professor at the University of South Carolina.\nTempleton Global Income’s (ticker: GIM) discount to NAV could narrow further if Saba acquires more shares or tries to take over the fund’s $743 million in assets. Saba recently took over management of another fund, Voya Prime Rate Trust, which it rebrandedSaba Capital Income & Opportunities(BRW).Franklin Templetonand Saba declined to comment.\nMiller/Howard High Income Equity(HIE) is also in Saba’s crosshairs. The fund is a “term trust” with a mandated liquidation date in 2024. It trades at a 5.9% discount to NAV. “In a worst-case scenario, you buy it at a discount and you’ll earn an excess return from now to 2024 because that discount will narrow,” says Patrick Galley, co-manager ofRiverNorth Opportunities(RIV), a closed-end fund that owns HIE.\nOther closed-end funds in which Saba owns stakes includeSource Capital(SOR) andInvesco Dynamic Credit Opportunities(VTA). Bulldog has built a position inTortoise Energy Independence(NDP).\nSome closed-end funds look attractive on their fundamentals.Adams Diversified Equity(ADX) offers exposure to big tech stocks, trades at a 14% discount to NAV, and is committed to an annualized distribution of at least 6%. “For investors who expect tech to do well, ADX is a good holding,” says David Tepper, a closed-end investor and head of Tepper Capital Management in San Francisco.\nSprott Focus Trust(FUND) is another fund he likes. Veteran small-cap manager Whitney George runs it, and his family owns 45% of the shares. It trades at a 10% discount and yields 5.7%. Tepper also favorsRoyce Global Value Trust(RGT), trading at a 9% discount and yielding 7.9%.\nNone of these funds has attracted much activist involvement, according to securities filings. But if activists see opportunity, they could pile in and pressure fund management—assuming that Congress doesn’t rewrite the rules of engagement.","news_type":1},"isVote":1,"tweetType":1,"viewCount":244,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}